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Abstract 
Background: The number of dialysis patients is steadily rising in Canada because of 
demographic changes as well as an increased prevalence of associated risk factors such as 
hypertension, diabetes, and aging (Clark & Khan, 2010). Therefore, survival analysis of 
dialysis patients and the investigation of factors associated with survival outcome is 
crucial. This study aimed to estimate the survival rate of dialysis patients in Grand River 
Hospital (GRH), compare the survival outcome of Peritoneal Dialysis (PD) and 
Hemodialysis (HD) patients and assess the factors affecting survival outcome.  
 
Methods: This retrospective study was based on the data on incident chronic dialysis 
patients (>30 days of dialysis) who initiated dialysis from January 2012 to September 
2017. Acute dialysis patients and those who initiated dialysis before the start of the study 
were excluded. Kaplan-Meier (KM) survival curves were generated to estimate the 
overall survival of the cohort as well as by different age categories, gender and, type of 
modality. The Cox Proportional Hazard (PH) model was used to identify variables 
significantly associated with survival outcome.  
  
Results: A total of 723 incident chronic dialysis with the average age of 64.86 years 
contributed to this analysis. The median survival time in this population was 39.8 months. 
Estimated 1-, 3- and 5- year survival rates were, 0.8, 0.54 and 0.34, respectively. Using 
the log-rank test, there was no statistical differences in survival outcome between patients 
undergoing HD and PD in this study (p=0.464). Backward elimination procedure with the 
two cut-offs (p>0.1 and p>0.2) resulted in two models in which hypertension was found 
to be significant in both (model A: adjusted HR = 0.62, p=0.013; model B: adjusted HR = 
0.65, p=0.023).  
 
Conclusion: This research showed comparable survival rates for incident chronic dialysis 
patients receiving care in GRH, similar survival experience of HD and PD patients and 
protective impact of hypertension on survival outcome. Long-term survival outcome 
results were similar between both groups; however, PD patients had an improved survival 
outcome during the first 18 months of the study.  
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 Chapter 1: Introduction 
 
Chronic Kidney Disease (CKD) refers to the progressive loss of renal function (i.e., 
“kidneys have not working properly to remove wastes and excess fluid from the body for at least 
three months”1). Among various medical problems, CKD is one the most serious, and its 
complications affect patients’ lives in many ways, such as decrease of their quality of life and 
loss of work ability. The prevalence of CKD is rising at an alarming rate worldwide, and the 
National Kidney Foundation (NKF) reports that about one out of every 10 people suffers from 
it2. In Canada, the number of patients receiving treatment for kidney failure has tripled in the last 
two decades2. 
 In the last stage of CKD, which is known as End-Stage Renal Disease (ESRD), the kidneys 
reach below 15 percent of their functionality (Clark & Khan, 2010). An ESRD diagnosis means 
that the kidneys have failed and are not working well enough to meet the daily needs of the 
patient’s body without any replacement. Dialysis and kidney transplantation are renal 
replacement therapies that provide permanent treatment and help patients in this stage survive 
(Clark & Khan, 2012). The Kidney Foundation of Canada has reported that out of 36,251 
patients with kidney failure, 58.5% are undergoing dialysis and 41.5% have a functioning 
                                                
1 Ontario Renal Network, kidney disease, retrieved at:  
http://www.renalnetwork.on.ca/info_for_patients/kidney_disease/ - .W1Tq760ZP-Y 
2,2,3 Kidney Foundation of Canada, Facing the Facts, 2017, retrieved at:  
https://kidney.ca/file/kidney.ca_nat/Facing-the-Facts-Kidney-Disease-2017.pdf 
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transplant3. Kidney transplantation is the optimal treatment option in ESRD population with 
regards to quality of life and survival potential. However, due to the shortage of available organs, 
dialysis is the main care mode for ESRD patients (Valderrábano, Jofre & López-Gómez, 2001). 
Hemodialysis (HD) and Peritoneal Dialysis (PD) are the most commonly used types of dialysis. 
Survival comparison of these two therapies has been investigated in several studies but survival 
advantage of each modality over the other is still inconclusive (Sood et al., 2012).  
In the past half-century, the widespread use of dialysis among the kidney-failure population 
can be considered as a remarkable achievement. Nevertheless, in spite of significant 
improvements in the availability of renal replacement therapies and a reduced mortality rate 
among ESRD patients, the mortality rate has still remained high compared with the rate in the 
general population (Arogundade, Sanusi, Hassan & Akinsola, 2011). The high rate of mortality 
among dialysis patients after initiation of the therapy can be attributed to many factors. 
Demographic factors, comorbidities, blood markers such as albumin and hemoglobin, and type 
of modality can contribute to survival (Collins, 2012). Additionally, receiving different levels of 
care can also affect survival, which leads to different survival rates in many countries (Wen et 
al., 2008; Yang & Hwang, 2008).   
Our present knowledge of the reasons leading to increased mortality among dialysis patients 
is still incomplete. Moreover, current understanding regarding the superiority of HD and PD is 
not sufficient. The use of survival analysis enables important interpretation to be made in terms 
of impact of various factors on survival outcome as well as comparing survival rate of patients 
undergoing different modalities. The knowledge gained could be used to provide 
recommendations to personalized care plan for patients. The overall aim of this study was to 
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address the aforementioned knowledge gaps, to better understand the mortality determinants and 
survival comparison of PD and HD patients in GRH. 
 This thesis will be divided into six chapters. The present chapter briefly addresses the 
problem and general aim of the study. In the second chapter, an overview of the CKD, ESRD, 
dialysis and their corresponding prevalence all around the world and in Canada is reviewed. A 
discussion on the factors associated with the survival as well as survival analysis description is 
also presented in chapter two. Subsequently, in chapter three study rationale and research 
questions will be provided. The fourth chapter, the methodology and design of the current study, 
including a description of the variables, the outcome, and statistical methods will be described. 
Next chapter presents the results of this study, including Kaplan-Meier survival curves as well as 
obtained Cox regression results. In the last chapter, a discussion of the results in addition to the 
strengths, limitations, future direction and conclusion of this study will be provided.  
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 Chapter 2: Literature Review 
 
2.1. Chronic Kidney Disease 
Chronic Kidney Disease (CKD) refers to a serious illness condition occurring 
progressively with significant health consequences. Cardio-vascular disease, hypertension 
and obesity consequences are among the most common causes of renal failure (Collins, 
2012). Clinically, there are five stages for CKD defined based on measuring the Glomerular 
Filtration Rate (GFR).  According to the National Kidney Foundation (NKF), End-Stage 
Renal Disease (ESRD) refers to the last stage of CKD in which the level of GFR is less than 
15 ml/min/173m2 1. 
In this stage, the kidneys fail to work at a level required for daily life. In fact, the gradual 
loss of kidney function reaches an advanced stage in which the metabolic needs of the 
patient’s body cannot be adequately met. ESRD patients who do not have the chance to 
receive Renal Replacement Therapy (RRT) are prone to death due to significant metabolic 
dysfunction and electrolyte imbalance caused by progressive deterioration in their renal 
function.		
Under this condition, patients require RRT which provides an artificial function of their 
kidney, extend life and alleviate the symptoms. RRT is considered as a life-saving 
intervention consist of three primary techniques, including Peritoneal Dialysis (PD), 
Hemodialysis (HD) and transplantation (Abecassis et al., 2008). Among these different 
                                                
1 National kidney foundation (NKF), 2017, retrieved at: https://www.kidney.org/atoz/content/gfr 
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therapies, transplantation is the most preferred therapy for patients. However, due to shortage 
of kidney donors, majority of ESRD patients need to initiate dialysis (Abecassis et al., 2008; 
Sayin, Colak, Tutal & Sezer, 2013). Of note, dialysis only performs the filtering function of 
the kidney, which is removing metabolic waste products and balancing electrolytes. In fact, 
production of hormones is not performed by dialysis (Abecassis et al., 2008). 
 
2.2. Dialysis  
Dialysis is a method of RRT, defined as the process of bidirectional flow of molecules 
across a semipermeable membrane. This procedure occurs in and out of the blood, across a 
semipermeable membrane. If molecule exchange happens outside of the body through an 
artificial membrane, the process is called HD or Hemofiltration (HF) (Daugirdas & Blake, 2012). 
If this process takes place across the peritoneal membrane, the process is named PD (Ahmad, 
2009).  
2.2.1. Hemodialysis 
HD modality involves the extracorporeal removal of waste products (e.g., creatinine and 
urea). This type of modality can be categorized based on the location as in-center HD and home 
HD (Daugirdas & Blake, 2012). Moreover, it can be also categorized as conventional, daily, 
short daily, and nocturnal. Regular HD is most often conducted in a hospital setting and is 
offered 3 times weekly for 3-5 hours for each session. Out-patient HD can be self-initiated or 
managed jointly with nurses and technicians or a trained helper, usually a family member. A 
nephrologist decides on dialysis parameters, including session length, session frequency, blood 
and dialysis solution flow rates and dialyzer size. Main disadvantages of this modality are 
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limited independence, restricted in fluid intake, complicated procedure, and expensive settings 
(Daugirdas & Blake, 2012).  
Moreover, HD procedure involves diffusion of solutes across a semipermeable membrane 
as well as fluid removal or ultrafiltration in which water and some dissolved solutes are moved 
across the membrane. Primarily there are two main methods for accessing blood for 
hemodialysis: Arteriovenous (AV) fistulas or grafts and catheter. In an AV fistula access type, an 
anastomosis is created between the artery and a native vein in which the blood flows directly 
from artery to the vein. However, in graft, the distance between the feeding artery and vein is 
bridged by a tube (i.e., created from a prosthetic material) (Daugirdas & Blake, 2012; Ahmad, 
2009).  
 
Figure 1. Schematic of the Hemodialysis (HD) procedure. From “MediResource Inc”, 2018, 
https://medbroadcast.com/procedure/getprocedure/hemodialysis?_ga=2.118604745.1125548109.153057
0499-774011722.1530570499 
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2.2.2. Peritoneal dialysis 
PD provides a home-based therapy with a simple equipment setup. In this type of therapy, 
the flow of solutes and water circulates across a membrane that separates two fluid-containing 
compartments. One compartment holds blood from the peritoneal capillaries (in renal failure it 
contains waste products such as the excess urea, creatinine, and potassium) and the other holds 
dialysis solution in the peritoneal cavity (it contains sodium, chloride and lactate). During the 
process of PD, as with the other methods, three transport processes occur simultaneously: 
diffusion, ultrafiltration, and absorption. 
PD is recommended more often for patients with difficult vascular access, such as infants 
or young children and patients with severe cardiovascular disease. This modality is less 
expensive (particularly in developing countries), more convenient and simpler compared to HD 
technique because of its home-based setting (Ahmad, 2009). There are two main types of PD: 
Continuous Ambulatory Peritoneal Dialysis (CAPD) and Automated Peritoneal Dialysis (APD)/ 
Continuous Cycling Peritoneal Dialysis (CCPD). In the CAPD procedure, solution changes 
should be performed by a patient four or five times per day; whereas these exchanges are carried 
out automatically in APD during the night when a patient is connected to the cycling machine 
(Daugirdas & Blake, 2012). 
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Figure 2. Schematic of the Peritoneal Dialysis (PD) procedure. From “MediResource Inc”, 2018, 
https://bodyandhealth.canada.com/channel/kidney-health/kidney-disease-management/peritoneal-dialysis 
 
2.3. ESRD and dialysis trend in Canada 
ESRD patients experience a broad range of distressing symptoms such as poor quality of 
life, increased risk of mortality and cardiovascular diseases (Tonelli et al., 2006).  In spite of 
epidemiological advances to reduce the prevalence of kidney disease globally, the prevalence 
of ESRD still remains high. Kidney Foundation of Canada in 2017 has reported that the 
number of Canadian suffering from ESRD has increased 36% since 20061. In 2015, Canadian 
Institute for Health Information (CIHI) reported that 35,281 Canadians (excluding Quebec) 
were living with ESRD2.  Out of this number 58.5% are receiving dialysis and the remaining 
                                                
1 Kidney Foundation of Canada, Facing the Facts, 2017, retrieved at: 
 https://kidney.ca/file/kidney.ca_nat/Facing-the-Facts-Kidney-Disease-2017.pdf 
2 Annual Statistics on Organ Replacement in Canada: Dialysis, Transplantation and Donation, 2006 to 2015, 
January 2017, retrieved at: https://www.cihi.ca/sites/default/files/document/corr-snapshot-en-webaccessible.pdf 
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have a functioning transplant.  Moreover,  patients above 65 years old were 47% of the whole 
number of Canadian ESRD patients1.  
 
2.4. ESRD and dialysis trend in Ontario and GRH 
Ontario Renal Network (ORN) survey examined the trend in 2016 and presented the data as 
the “The Ontario 2016 CKD System Atlas”.  The data reported the information on CKD and 
ESRD patients in 26 regional CKD programs as well as the corresponding multidisciplinary 
clinics in Ontario from 2010 to 2015. An increasing trend has been reported in the number of 
incident patients with advanced CKD since 2013. The prevalence of this group of patients 
increased from 5335 in 2013 to 6396 in 2015 in Ontario. It is worthwhile to mention that the 
increase in patients count over time was higher among elderly patients (particularly over 65 years 
old)2.  
According to 2016 CKD System Atlas, since 2010, the provincial rate of increase in the 
incident number of patients initiating chronic dialysis is 3.3% annually. This number was 3069 in 
2015. Out of 6396 patients newly registered in Ontario with advanced CKD, 337 new dialysis 
patients were registered at GRH in Waterloo region in 2015. In the duration from January 1, 
2015 to December 31, 2015, 3069 patients started chronic dialysis in Ontario and GRH 
represents approximately 5% of the whole1. Different growth rate was observed across different 
                                                
1 Kidney foundation of Canada (2017), Facing the facts about kidney disease. Retrieved at : 
https://kidney.ca/file/kidney.ca_nat/Facing-the-Facts-Kidney-Disease-2017.pdf 
2 Ontario Renal Network. Ontario 2016 CKD System Atlas: Trends in Kidney Disease and Care. Toronto: Ontario 
Renal Network, CCO; 2016, retrieved at: 
http://www.renalnetwork.on.ca/common/pages/UserFile.aspx?fileId=362165 
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age categories in Ontario. For example, the category of 65-74 years old patients had the highest 
growth rate. The number of patients initiated dialysis in 2015 was around 700 in Ontario1.  
 
2.5. Distribution of modalities in Canada and Ontario  
        Based on the latest reports from CIHI in 2015 the number of Canadian patients who started 
incident chronic dialysis therapy in terms of modality were reported as follows: 76.6% 
institutional HD (n=4004), 0.7% home-HD (n=36), 12.6% CAPD (n=632) and 7.3% APD 
(n=368)1. According to the ORN recent report in 2016, 78.8% (n=2393) of ESRD patients were 
initially started the therapy with in facility-based HD and 20.7 % (n=644) with PD. The number 
of incident home HD patients were only 0.5% (n=15)2.  
 
2.6. Survival analysis 
Survival analysis refers to a popular data analysis for specific types of epidemiologic 
data and analytic problems. Survival analysis is defined as “a collection of statistical 
procedures for data analysis for which the outcome variable of interest is time until an 
event occurs.” (Kleinbaum & Klein, 2006, p.4). There are two common concepts in the 
context of survival analysis, time and events. Time is measured in years, months, weeks 
                                                
1 Annual Statistics on Organ Replacement in Canada: Dialysis, Transplantation and Donation, 2006 to 2015, 
January 2017, retrieved at: 
 https://www.cihi.ca/sites/default/files/document/corr-snapshot-en-webaccessible.pdf 
2 Ontario Renal Network. Ontario 2016 CKD System Atlas: Trends in Kidney Disease and Care. Toronto: Ontario 
Renal Network, CCO; 2016, retrieved at: 
http://www.renalnetwork.on.ca/common/pages/UserFile.aspx?fileId=362165 
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or days from the beginning of the induvial entry to the study until to the occurrence of the 
event of interest, such as death, disease occurrence, recovery or any other designated 
experience that may happen to an individual. In the context of survival analysis, “survival 
time” refers to the time that an individual survived over the study follow-up time period 
(Kleinbaum & Klein, 2006). 
2.6.1. Survival analysis goals 
The main purposes of survival analysis are to estimate, interpret and compare the main 
quantities, including survival and (or) hazard functions and also to estimate the impact of various 
covariates on survival time. The objectives in a survival analysis may include estimation of one 
or more of these statistics in specified covariate profiles and quantifying the influence of 
explanatory variables (e.g., treatments, demographics) on survival. These goals can be achieved 
through modeling how x (i.e. explanatory variables) impacts T (i.e., survival time) directly or 
indirectly (George, Seals & Aban, 2014).  
2.6.2. Censored data  
Censoring is one of the most important analytical problems for survival analysis in the 
design of clinical trials. It occurs when information on the times to events of interest is not 
available for all the included individuals in a cohort (Singh & Mukhopadhyay, 2011). An 
important fact about censored data is that this type of analytical problem is not considered as 
missing values. In other words, statistical survival analysis is able to include this type of data in 
building the model.  
  
12 
There are two types of censoring: right and left. In the context of health studies, when a 
patient does not experience the event of interest or outcome (i.e., lost to follow-up or experiences 
censoring events) during the study period, right censoring has occurred (Singh & 
Mukhopadhyay, 2011). Right-censored data are more common in the context of health care 
compared to left-censored observation (Prinja, Gupta & Verma, 2010). Left censoring refers to a 
condition in which the patient has been exposed to the disease before entering to a study (i.e. the 
exact time of exposure is not clear).  In other words, the survival time is incomplete on the left-
side of follow-up duration. In this study, there was no left censoring. 
Figure 3 depicts the study time for eight patients in a clinical trial in which entry to the study 
shown is with a “●”. Patients 1, 4, 5 and 8 die (D) during the study period, while patients 2 and 7 
are lost to follow-up (L), and only patients 3 and 6 are still alive at the end of the study.  The 
corresponding survival time for the individuals is calculated from entry to the study until the 
death of patients (D). This period can be calculated for patients 1, 4, 5 and 8. The survival times 
of patients 2, 3, 6 and 7 are right-censored (Collett, 2015).   
 
Figure 3. study time for eight patients in a survival study 
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When the probability of any patient in the cohort being censored in the cohort at time t does 
not depend on the patient’s survival outcome at time t, non-informative censoring happens 
(Kleinbaum & Klein, 2006).  
2.6.3. Survival rate estimation 
The purpose of survival rate estimation for various medical problems is to identify the 
average prognosis in a specific population. Consequently, the obtained survival rate in the region 
concerned provides an index of the effectiveness of different treatments and medical care (Parkin 
& Hakulinen, 1991). Survival rate can be defined as “the percentage of people in a study or 
treatment group who are still alive for a certain period of time after they are diagnosed with or 
have started treatment for a disease, such as cancer.”1 In the survival analysis context, an initial 
analysis would typically employ nonparametric methods to estimate the survival function and 
summary statistics such as survival rates, and a comparison across several groups or sub-
populations (Gardiner, 2010). The widely used analytical method to estimate survival rates for 
population-based data is Kaplan-Meier estimator which will be discussed in Methods chapter 
(4.7.2). 
2.7. Survival rate in dialysis patients 
In the medical research context, survival analysis is generally considered as one of the most 
clinically relevant statistics to estimate the patients’ prognosis, chance of survival or recovery, 
                                                
1 NCI dictionary of Cancer Terms, retrieved at: http://www.cancer.gov/ 
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and to identify the most optimized treatment plan. In public health research, survival statistics are 
represented by survival rates as an important indicator of health status of a specific population. 
Due to multiple health concerns affecting life expectancy of dialysis patients, nephrologists’ 
efforts have been directed towards improving this rate. The last years, have seen some 
remarkable improvements in the field of dialysis leading to increased quality of life and 
facilitated dialysis procedure. Despite some evidence showing decrease in overall mortality rate 
over the past two decades, the survival rate and life expectancy did not improve significantly 
among dialysis patients (Arogundade et al., 2011).   
The Canadian dialysis population experienced gradual improvement in long-term survival 
rates for all modalities. Reports on data from the Canadian Organ Replacement Register (CORR) 
demonstrated that the 5-year survival rate increased from 0.38 in 2006 to 0.43 in 2010 among 
hemodialysis patients1. Likewise, the same trend was observed for the 3-year survival rate.  
Another study conducted in Korea in 2015 reviewed over 32,000 incident dialysis patients, 
to explore whether the survival rate improved from 2005 to 2008. Kaplan-Meier curves 
demonstrated statistically significantly different survival rate in terms of dialysis initiation year 
(p=0.005), particularly among PD patients compared to group HD (p<0.001) (Ryu et al., 2015). 
The 1-, 2-, 3-, and 4-year survival rate improved from 87.6, 78.2, 70.4, 64.4 in 2005 to 88.6, 
80.1, 73.0, 66.8 in 2008, respectively. The significant differences in survival rates persist after 
multivariate analysis which revealed lower mortality risk of patients initiating any type of 
dialysis including PD or HD in 2005 compared to 2008. In the Cox model, age (per 1-year 
                                                
1 Canadian Organ Replacement Register (CORR) at the Canadian Institute for Health Information (CIHI), 2016, 
retrieved at: https://www.cihi.ca/en/canadian-organ-replacement-register-2016 
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increase, HR 1.05, p<0.001) female gender (vs. male, HR 0.85, 95% CI, p<0.001) grade 5 or 
higher for Charlson Comorbidity index (CCI) (vs. grade 0, HR 2.67, CI 95%, p<0.001), and 
Medical Aid (vs. National Health Insurance, HR 1.71, 95% CI, p<0.001) were significant 
independent predictors of mortality. Of note, dialysis modality did not have any statistically 
significant impact on survival (HD vs PD, HR=0.91, p=0.052). Subgroup analysis of the cohort 
showed a higher survival rate of non-diabetic patients younger than 65 years old who received 
PD in 2008 relative to the counterparts undergoing HD. Furthermore, this study found no 
statistically significant differences in mortality rate among patients younger than 55 years old 
(Ryu et al., 2015). 
Recently, in Iran a retrospective study by Shabankhani et al., (2016) analyzed the survival 
rate of 500 hemodialysis patients in three hospitals and also evaluated the variables influencing 
survival. During a 6-year follow-up the impact of gender, age, education, occupational status, 
smoking status, age at diagnosis, primary cause of renal disease, age at initiation of dialysis, 
living with family, cardiovascular disease, and weight were assessed using Cox proportional 
hazard model. Median survival time was 108 months and the mortality rate was 34.8% (174 
deaths).  Multivariate Cox analysis showed statistically significant impact of being illiterate 
(p=0.03), smoking status (p=0.02), being unemployed (p=0.03), age (p<0.001), renal cyst 
(p=0.02), congenital disease (p=0.001), or other unspecified conditions (p=0.03) as the cause of 
renal diseases on survival outcome. The study also estimated the 1-, 2-, 3-, 5-, 10-, and 12-year 
survival rate for this cohort as 84%, 77%, 71%, 58%, 43%, and 33%, respectively (Shabankhani, 
Kazemnejad, Zaeri, Espahbodi, Ahmadi & Mirkazemi, 2016).  
In a retrospective study by Ahmad and Shahzad in 2015, the survival rate of a sample of 40 
patients receiving dialysis in two hospitals in Lahore, Pakistan and the influence of different risk 
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factors on outcome were analyzed. The survival distribution of factors including age (classified 
as “<=50 years” and “>50 years”) and comorbid factors (classified as none, peripheral vascular 
disease (PVD), hypertension, chronic respiratory disease, hepatitis, diabetes, Ischemic Heart 
Disease (IHD), more than one diseases) were extracted using log rank (Mantel-Cox).  At 5% 
significance, the survival distribution of age (p=0.012) and comorbid factors (p=0.008) were 
statistically significantly different. Multivariate Cox regression analysis demonstrated the 
statistically significant impact of Body Mass Index (BMI) (p=0.026), serum albumin (p=0.024), 
and family history of diabetes (p=0.001) on survival.  However, the hazard of the variables in the 
survival of patients was not the same as the family history of diabetes (HR=0.001, 0.008 for type 
one and two respectively), and BMI (HR=0.88) reflected less hazard than serum albumin 
(HR=14.796) (Ahmad & Shahzad, 2015). These findings revealed the extreme vulnerability of 
dialysis patients compared to the general population.  
 
2.8. Factors associated with mortality among dialysis patients 
When commencing dialysis, several important factors should be taken into account by 
clinicians. These variables can be grouped into demographics, type of modality and comorbid 
conditions and physiology indicators.  
2.8.1. Demographic characteristics 
Demographic factors such as age, gender, BMI and ethnicity/race that affect survival are still 
only partially understood among patients with renal problems.  
Age: Older age is considered as a prognostic factor for poor clinical outcome in incident 
dialysis patients (Sayin et al., 2013; Tonelli et al., 2006; Klarenbach, Tonelli, Chui, Manns BJ, 
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2014; Ryu et al., 2015; Shabankhani et al., 2016; Thijssen, Usvyat & Kotanko, 2012). According 
to Thijssen et al. (2012), HD patients aged 65 years old and above have a six times higher risk of 
mortality relative to general population. In this study age was strongly indicated to be significant 
in specific time periods after starting HD (p<0.0001, 95% CI, 1.018-1.046). Similarly, 
Shanbankhani et al. (2016), found that age is highly associated with mortality and poor survival 
prognosis among hemodialysis patients (HR=1.033, p<0.001). In a recent Canadian study, 
elderly patients (65 years old and above) experienced increased risk of mortality in both PD and 
HD group of patients (HR= 1.27, 1.41, 95% CI, 1.04-1.26, 1.04-1.27, respectively) (Yeates et al., 
2012). In keeping with these findings, 1-year increase in age increased risk of death of Korean 
dialysis patients with the hazard ratio of 1.05 (95% CI, 1.05-1.06, p<0.001) (Ryu et al., 2015).  
Gender: Role of gender as an independent prognostic factor for mortality is inconclusive 
among dialysis patients. Thijssen et al. (2012), found significant impact of gender on mortality 
only in certain time periods after initiation of dialysis (p<0.0001, 95% CI, 1.068-2.16). The 
findings of this study reflect vulnerability of male sex to mortality. However, Yeats et al. (2016), 
indicated that female gender is highly correlated with mortality for both age groups including 18-
64 and above 65 years old among Canadian dialysis patients (HR= 1.1, 1.27, 95% CI= 0.98-1.25, 
1.04-1.26, respectively). While in Korean dialysis population gender is not considered as a risk 
factor for death, recent comprehensive investigation of dialysis patients in South Korea revealed 
that female sex was associated with decreased risk of mortality (HR=0.85, 95% CI= 0.78-0.92, 
p<0.001) (Ryu et al., 2015). In some studies, gender does not contribute to death in dialysis 
patients. For instance, survival analysis of incident HD patients in Iran revealed that gender is 
not associated with mortality (HR=0.45, p=0.09). A survival analysis of 500 HD patients in 
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Mazandaran, Iran using three hospitals during a 6-year study period demonstrated non-
significant effect if gender on mortality (HR=0.44, p=0.09) (Shabankhani et al., 2016).  
BMI: Numerous studies have attempted to investigate the impact of BMI on survival of 
patients undergoing dialysis. Existing evidence reveals that patients with high BMI are more 
prone to ESRD compared to the general population. Therefore, an increase in prevalence of 
obesity among ESRD patients requiring dialysis is becoming the focus of epidemiologists’ 
research (Hsu, McCulloch, Iribarren, Darbinian & Go, 2006). It is reported that mean BMI has 
been increased in some countries. For example, among American incident ESRD patients, the 
mean BMI increased to 27.5 kg/M2 in 2002-2007 from 25.7 kg/M2 in 1995 (Kramer et al., 
2006). Given this background, while the general population is encouraged to lower their BMI, 
incident dialysis patients are more likely to survive when their BMI is higher. It can be explained 
by two underlying reasons: first, high prevalence of malnutrition among dialysis patients (Badve 
et al., 2014). Malnutrition-inflammation syndrome (MIS) is one of the extremely common 
problems among dialysis patients and a possible risk factor for mortality (Kalantar-Zadeh, 
Kopple, Block & Humphreys, 2001).  Nutrition loss through dialysis process, oxidative and 
carbonyl stress, existence of comorbid conditions, low nutrient intake and anorexia owing to loss 
of appetite, are all counted as potential causes of MIS (Kalantar-Zadeh, Ikizler, Block, Avram & 
Kopple, 2003).   
Dialysis risk paradox refers to paradoxical relationship between mortality and several factors 
such as BMI, blood pressure and serum albumin (Speakman & Westerterp, 2010). Numerous 
studies have reported the survival advantage of high BMI over low BMI for dialysis patients. 
The systematic review of literature on the association between survival and BMI from 1982 to 
2002 revealed improved survival outcome for those with high BMI (Salahudeen, 2003). 
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Furthermore, these findings are consistent with those reported by Badve et al., (2014). This large 
registry study showed that higher baseline BMI (i.e., 28-34 kg/m2 for HD patients and 34-37 for 
PD patients) is associated with better survival outcome. In addition to baseline-BMI 
measurements, the association of time-varying BMI for both groups of PD and HD with 
mortality has been examined. It was concluded that time-varying measures of BMI were also 
significantly affecting mortality in both HD and PD patients (Badve et al., 2014). Another study 
involving Taiwanese population undergoing hemodialysis, found survival disadvantage of low 
BMI (i.e., less than 18.5 kg/m2) (Huang, Cheng & Wu, 2008). In the cohort of 109,605 
maintenance HD patients, both obesity (BMI>30 kg/m2) and morbid obesity (BMI>40 kg/m2) 
were associated with longer survival (Ricks et al., 2011). It is worthwhile to mention that this 
association appeared to be more evident in blacks and the weakest in Hispanic maintenance HD 
patients relative to non-Hispanic patients. In fact, the survival benefit of obesity was more 
prominent in this ethnic group. These findings represent the protective but differential role of 
high BMI across different ethnic groups (Ricks et al., 2011).   
However, recent studies have highlighted the limitations of BMI in the dialysis population as 
a reflection of body composition. There is uncertainty regarding which components of body 
composition (i.e., fat and body mass) are associated with survival outcome. As a result, it is 
challenging to quantitatively understand which components of body composition can affect 
survival in dialysis patients.   
Race: Reports on role of racial and ethnic differences in survival of dialysis patients remains 
controversial. In US, the lifespan for black people is 4-5 years less than their white counterparts 
due to worse economic status, genetic differences affecting development of some diseases, 
differences in income and education, cultural disparities in the health behaviors and attitudes as 
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well as poorer access to care settings (Kochanek, Xu, Murphy, Miniño & Kung, 2002; Powe, 
2008; Wong, Shapiro, Boscardin & Ettner, 2002).  However, on the last stages of CKD better 
survival is reported for black patients over white patients (Jolly et al., 2011). Particularly in 
dialysis patients, a lower annual mortality rate (18%) is observed among black patients than non-
Hispanic whites (23%) (Collins et al., 2005). 
In the analysis of DaVita maintenance HD patients for the duration of 6 years, lower 
mortality rates are observed among black and Hispanic dialysis patients compared to non-
Hispanic whites (Ricks et al., 2011). Along with this finding, Bradbury’s retrospective sample 
from the dialysis outcomes and practice pattern study (DOPPS) in US found that white race is 
among the significantly elevated risk factors for mortality during the first 120 days after dialysis 
initiation. In the subsequent 121 to 365 days after dialysis, white race remained as a strong 
predictor for mortality (Bradbury et al., 2007). The finding of this study about the strength of 
white race and old age as mortality risk factors is consistent with some other studies involving 
prevalent hemodialysis patients (Goodkin et al., 2003; Ma, Ebben, Xia & Collins, 1999).  
In a more recent analysis of the national United States Renal Data System (USRDS), 
observed mortality rate in the black population was lower compared to the non-Hispanic white 
group. The exception only applies to the youngest sub-population (18-30 years) in which 
survival is longer relative to their non-Hispanic white counterparts (Yan et al., 2013). There are a 
few reasons explaining the commonly cited survival advantage of blacks compared to non-
Hispanic whites particularly in the older age group. Although the reasons are not well-defined, 
they may justify the phenomenon. These consist of different inflammatory responses (Crews, 
Sozio, Liu, Coresh & Powe, 2011), different cultural adaptation in chronic conditions (Norris, 
Kalantar-Zadeh & Kopple, 2011), different delays in time to transplantation (Hall YN, Choi AI, 
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Xu P, O'Hare AM, Chertow, 2011), healthier nutritional and inflammatory status (Streja et al., 
2011) and being treated with active vitamin D (Kalantar-Zadeh et al., 2010). Additionally, many 
studies provide strong evidence regarding survivorship biases due to receiving less pre-ESRD 
care among black population (Bethesda, 2011).  
 
2.8.2. Type of modality 
Given the wide prevalence of ESRD and growing economic burden of dialysis on health 
care systems, dialysis modality choice becomes a momentous issue. Evidence regarding the 
survival comparative effectiveness of HD and PD should be interpreted cautiously due to 
potential biases. Lack of randomized controlled clinical trials and mainly prospective study 
design provide information on the effectiveness dialysis modality rather than on causality 
relationships between modality and mortality (Yang et al., 2015). 
 In order to explore the existing differences between two treatment techniques among 
incident dialysis, fourteen relevant studies published in PubMed across the last ten years were 
reviewed in January 2017. The specific aim of this review was to analyze the impact of modality 
on mortality and compare different modalities outcome. Two primary research questions 
addressed by the review were focused on the independent variables included in the survival 
model, corresponding association with survival outcome, significant variables affecting survival 
as well as the outcome comparison for the two modalities.  The details about the result of the 
review including, context data, quantitative and qualitative findings, survival outcome 
distribution, executive summary of evidence regarding survival outcome for two modalities, and 
  
22 
cohort summary are presented in the Appendix A, B, C, and D. In what follows, a brief summary 
of the findings of the included studies will be discussed.  
Obtained results from the aforementioned review on assessing the survival outcome 
differences in HD and PD modalities were inconclusive. Of the 14 studies, 35% (n=5) reported 
similar outcomes for PD and HD (Huang et al., 2008; Madziarska et al., 2013; Lee, Sun & Wu, 
2009; Wang et al., 2016; Andrikos, Tseke, Balafa & Pappas, 2008). A further 35% of the studies 
revealed superior outcome of PD over HD (Yeates et al., 2012; Sood et al., 2012; Serafinceanu, 
Neculaescu, Cimponeriu, Timar & Covic, 2014; Marshall et al., 2015; Choi et al., 2013).  In one 
Canadian study by Sood et al. (2012), the survival outcome of PD was superior for both group of 
Aboriginal and Caucasian dialysis patients relative to HD. Similarly, Serafinceanu et al. (2014) 
found that hemodialysis as a first/single technique for RRT, is associated with increased risk of 
mortality. Choi et al. (2013), likewise found that patients under 65 years without diabetes have a 
better survival under PD than HD. In contrast, the final 30% (n=4) of studies demonstrated better 
survival outcome for patients undergoing HD treatment technique relative to PD (Yang et al., 
2015; Kim et al., 2014; Wang et al., 2013; Sens, Schott-Pethelaz, Labeeuw, Colin & Villar, 
2011).  
2.8.3. Comorbid conditions 
It is well-established that Cardio Vascular Disease (CVD) and diabetes are the most 
important co-exiting conditions that predict worse outcomes for dialysis patients (Miskulin et al., 
2009; Beddhu, Bruns, Saul, Seddon & Zeidel, 2000; Hemmelgarn, Manns, Quan & Ghali, 2003; 
Keane & Collins, 1994; Rostand, Kirk & Rutsky, 1982). Charlson Comorbidity Index (CCI) is 
one the frequently used scores in the studies to measure the impact of various comorbidities on 
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mortality (Miskulin et al., 2009). A number of studies have shown that increased in CCI is 
correlated with adverse outcomes among dialysis patients such as reduced quality of life, 
increased costs and mortality (Fried, Bernardini & Piraino, 2001; Beddhu et al., 2000). However, 
a validation study of CCI on ESRD patients indicated that since this score is designed for general 
population, the assigned weights do not generalize to the dialysis group of patients (Hemmelgarn 
et al., 2003). In a study by Goodkin et al. the correlation of various comorbid conditions and 
mortality was examined among hemodialysis patients in different geographic locations (Goodkin 
et al., 2003). Consistent with a number studies, Coronary Artery Disease (CAD), Congestive 
Heart Failure (CHF), cardiomegaly, other cardiac diseases, diabetes mellitus, Peripheral Vascular 
Disease (PVD), cerebrovascular disease, lung disease, cancer, HIV infection, gastrointestinal 
bleeding, neurologic disease, psychiatric disease, cellulitis/ gangrene, hepatitis, and smoking are 
significantly associated with poor outcome (Goodkin et al., 2003, Keane & Collins, 1994; Fried 
et al., 2001). Similarly, Miskulin et al. (2009), indicated that aforementioned comorbidities add 
independent prognostic information when clinical indicators and laboratory values are included 
in the model. Indeed, seventeen included comorbid conditions had more discriminatory power 
for survival compared to laboratory and clinical indicators (Miskulin et al., 2009). 
While these comorbidities are considered as strong predictors of mortality, the impact of 
hypertension as one of the most important risk factors for cardiovascular diseases on survival is 
still inconclusive (Rostand et al., 1982; Mazzuchi, Carbonell & Fernández-Cean, 1982; Rahman, 
Fu, Sehgal & Smith, 2000). Goodkin et al., (2003) also revealed a 26% decreased risk of 
mortality among patients with hypertension. Similarly, the protective role of high blood pressure 
in the pre-dialysis stage was also confirmed in some other studies previously (Besarab et al., 
1998; Iseki et al., 1997). 
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Diabetes: Survival among diabetic dialysis patients is inferior to nondiabetic dialysis patients 
(Liem, Wong, Hunink, Charro, & Winkelmayer, 2007). There are several studies in the literature 
that have analyzed the impact of diabetes on survival. For example, a recent review focusing on 
the evaluation of dialysis diabetic patients’ survival showed that both HD and PD diabetic 
patients had lower survival than those without diabetes (Ghaderian, Hayati, Shayanpour & 
Beladi, 2015). In a large international study by Schroijen et al. in (2013), the survival of dialysis 
patients with the history of diabetes as a comorbid condition was lower than those without the 
diagnosis of diabetes (HR=1.25, 95% CI=1.14-1.38). Similarly, retrospective survival analysis of 
897 HD patients in a duration of 4 years in India, indicated that diabetes as a comorbidity is 
associated with lower survival rate (HR=1.73, p<0.001) (Vijayan et al., 2016). Likewise, the 
analysis of large-scale cohort from the Italian Dialysis and Transplantation registry using Poisson 
regression indicated the strong association of diabetes with excess mortality (Relative Excess 
Risk (RER) = 2.91, 95 % CI, 2.5-3.38) (Nordio et al., 2012). In a survival comparison of HD and 
PD patients in a registry-based data in Taiwan diabetes was significantly associated with survival 
outcome (adjusted HR=1.99, p<0.001) (Wang et al., 2013). A systematic review aiming at 
estimation of the relative risk of death associated with specific characteristics of dialysis patients 
was conducted analyzing 24 studies (Joanna, Gore & Firth, 1999). Using quantitative techniques 
in this review revealed that the relative risk of mortality associated with the presence of diabetes 
as a comorbid condition was 1.91 (p<0.0001). Many factors contribute to the poor prognosis of 
diabetic patients on dialysis such as presence of cardiovascular disorders, foot ulcer and vascular 
access problems due to susceptibility to infections, etc. (Schroijen et al., 2013). In contrary to the 
adverse impact of diabetes on survival outcome of dialysis patients, there are some studies that 
highlighted the insignificant impact of diabetes on mortality. For instance, survival comparison 
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of HD and PD patients with the presence of Congestive Heart Failure (CHF) in France did not 
show any significant impact of both types of diabetes on death (diabetes type 1: HR=1.11, 
p=0.11), (diabetes type 2: HR=1, p=0.99) (Sens et al., 2011). Similarly, in a single center 
retrospective study in Germany, diabetes was found as an insignificant predictor of mortality 
(Koch, Hollenbeck, Trapp, Kulas & Grabensee, 2006).  
Hypertension: In ESRD population treated with HD and PD, the prevalence of hypertension 
is significantly high and often poorly controlled (Georgianos & Agarwal, 2016). The potential 
impact of elevated blood pressure on the occurrence of cardiovascular or cerebrovascular events 
has been well established in general population (Lim et al., 2012; Perkovic, Huxley, Y, 
Prabhakaran & MacMahon, 2007). Unlike this linear relationship between the blood pressure and 
mortality in general population, some reports indicate a paradoxical association between 
hypertension and survival outcome in dialysis patients (Kalantar-Zadeh, Kilpatrick, McAllister, 
Greenland & Kopple, 2005). This phenomenon referred to as “reverse epidemiology” confirming 
the role of hypertension as a protective feature that is associated with greater survival in dialysis 
population (Kalantar-Zadeh K, Block G, Humphreys MH).  
 Among chronic dialysis patients, pre-dialysis and post-dialysis recordings of blood 
pressure display a U-shape association between hypertension and mortality. To demonstrate, low 
and high blood pressures are associated with higher mortality in this group of patients (Zager et 
al., 1998). In a retrospective large sample study conducted by Zager et al. (1998), a U-shape 
relationship between Systolic Blood Pressure (SBP) and mortality was found. In a duration of 5 
years follow-up time, 433 HD patients were analyzed using Cox proportional hazard regression 
with time-varying covariates. Exploring the association between SBP and Diastolic Blood 
Pressure (DBP) on cardiovascular mortality in this population, demonstrated the significant 
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impact of low blood pressure on the increased risk of mortality. In both pre- and post-dialysis, 
low SBP identified as less than 110 mm Hg was strongly associated with the risk of 
cardiovascular mortality. Similarly, post-dialysis, SBP greater than 180 Hg (RR=1.96, p<0.015) 
and DBP above 90 Hg (RR=1.73, p<0.05) significantly increased the risk of cardiovascular 
mortality. Additionally, there was no relationship between both SBP and DBP and 
cardiovascular mortality, before initiating HD.  
On the other hand, there are several studies in the literature, highlighting the role of 
hypertension as a risk factor for increased risk of cardiac events and death. According to Foley et 
al. (1996), even moderate hypertension worsened the clinical outcome in both HD and PD 
dialysis patients particularly among those without a history of cardiac events.  Similarly, a study 
by Charra et al. (1992), showed that excellent survival results in 445 HD patients were 
attributable to improved blood pressure control. A retrospective cohort study of Indonesian 
Renal Registry applying time-dependent cox regression in the duration of 2007-2012 indicated 
the significant effect of diabetes and hypertension on mortality among hemodialysis patients with 
the hazard ratio of 1.17 and 1.04, respectively (Purnama, Riono & Farid, 2015).  
     A study by Lucas et al., (2003) investigated the effect of hypertension in survival outcome of 
184 HD patients before commencing dialysis. Conventional Cox proportional hazard model was 
utilized adjusting for age, sex, albumin, vascular calcification, history of hypertension and 
comorbidity. History of hypertension was defined as the average of three blood pressure 
measurements per year during the outpatient’s study follow-up. Based on this categorization, 
three groups were identified as the history of hypertension: normotensive, controlled 
hypertensive with therapy and uncontrolled hypertensive despite treatment. The threshold for 
normal or controlled hypertension was considered less than 140/90 mm Hg. Comorbidity 
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(HR=1.95, p=0.003) and uncontrolled hypertension (HR=1.79, p=0.01) were highly associated 
with all-cause mortality. For cardiovascular mortality, uncontrolled hypertension before 
initiating dialysis was an independent risk factor (HR=2.93, p<0.05).  
There are also some studies that found the nonsignificant effect of hypertension on the 
survival of dialysis patients. For example, in a prospective study by Tong J et al., in 2016 
survival analysis of 591 dialysis patients in two centers revealed nonsignificant effect of 
hypertension as a comorbidity and SBP on all-cause mortality. In this study presence of 
hypertension as a comorbidity identified if the patient was under antihypertensive medication or 
had two measurements for blood pressure in different occasions greater than 140/90 mmHg. In 
contrast, the DBP was found as an independent risk of mortality (HR=0.976, p=0.015).  
Cancer: History of cancer as one of the common comorbidities can be associated with 
adverse outcome among chronic dialysis patients.  For example, in a study by Floege et al in 
(2015), history of cancer was found as to be a significant risk factor for 1 and 2- year mortality 
among incident HD patients (HR=1.75, 95% CI=1.49-2.05). Similarly, survival analysis of 35, 
664 dialysis patients in Taiwan indicated the significant impact of cancer on survival outcome 
(HR=1.25, p<0.001) (Wang et al., 2013). In spite of the significant impact of cancer on mortality 
in dialysis population, some other studies indicated the nonsignificant impact of this comorbidity 
on the outcome. In a retrospective study by Béchade et al. (2017), survival outcome of incident 
chronic dialysis patients with a previous diagnosis of cancer was evaluated. Using KM survival 
curves and stratified Cox model, survival of patients with and without cancer was not different 
and the history of cancer was not associated with death (HR=0.96, p=0.8). Survival analysis 
population-based data of 975 HD and PD patients with the history of prior stroke in Taiwan, 
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indicated that cancer was not associated with survival (HR=0.62, 95% CI=0.28-1.37) (Wang et 
al., 2016). 
Stroke: Like other comorbidities such as diabetes, stroke is also common among patients 
undergoing chronic dialysis but how it is associated with survival outcome is still unknown 
(Wetmore, et al., 2014).  Retrospective analysis of 69, 371 long-term dialysis patients using a 
semi-Markov model revealed that dialysis patients experienced higher mortality after ischemic 
and hemorrhagic stroke. The corresponding adjusted HRs for ischemic and hemorrhagic stroke 
were 1.7 (p<0.0001) and 1.3 (p<0.001) at 36 months (Wetmore, et al., 2014). In a prospective 
cohort study of 591 dialysis patients using multivariate Cox model, stroke was an independent 
predictor of all-cause mortality among dialysis patients with the presence of CVD (HR=4.57, 
p<0.001) (Tong et al., 2016). Another study in Taiwan also assessed the risk of mortality among 
5672 HD patients with and without the history of stroke. Using multivariate Cox model in this 
study indicated that history of stroke at the time of starting dialysis is an important predictor of 
all-cause mortality among incident HD patients (HR=1.36, p<0.001) (Chien et al., 2013). In 
contrary to these findings, some other studies did not find any significant impact of stroke on 
survival outcome such as an observational study by Cherukuri & Bhandari in 2009. In this 
prospective study using data from a dialysis center in the UK, history of stroke was not 
associated with survival outcome (Cherukuri & Bhandari, 2009).   
Cardiac disease: Coronary Artery Disease (CAD) is the most common type of cardiac 
disease and as a comorbid condition contributes to the increased risk of mortality among dialysis 
population (Chou & Fang, 2013). Moreover, the presence of Myocardial Infarction (MI) as a 
comorbidity can also worsen the survival outcome of dialysis patients. For example, analysis of 
15,245 incident HD and PD patients in a 3-year study showed that MI was associated with 
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increased risk of early mortality among younger patients (i.e., <45) in this population (Odd 
Ratio=8.8, 95% CI= 4.2-18.6) (Soucie & McClellan, 1996). Survival analysis of 35, 664 PD and 
HD patients in a duration of 10 years follow-up found the significant impact of CAD on survival 
outcome (HR=1.14, p<0.001) (Wang et al., 2013).  Survival comparison of chronic HD patients 
with and without the history of stroke in Taiwan revealed that presence of CAD was associated 
with increased risk of all-cause mortality in this population (HR=1.88, p=0.003) (Chien et al., 
2013). Another study by Goodkin et al. (2002), using DOPPS registry data found CAD as a 
significant predictor of mortality (RR=1.31, p=0.001).  
In contrast, some other studies in this context showed that pre-existing CAD was not 
associated with survival outcome in dialysis population. A prospective study in Japan using 947 
HD patients’ data examined the predictive value of various variables for mortality. Appling Cox 
model in this study indicated that CAD was a nonsignificant predictor of mortality among long- 
term HD patients (HR=1.46, p=0.290) (Ajiro et al., 2007). This finding was in line with others 
such as studies by Lawton et al. (2015), and Andrikos et al. (2008), in which CAD was an 
insignificant variable in the survival analysis of dialysis patients.  
Lung disease: There is an increasing evidence that presence of lung disease disorders could 
lead to an adverse outcome in dialysis population. For instance, analyzing HD patients’ data in 
DOPPS registry by Goodkin et al., in 2002 indicated the increased risk of mortality in the 
presence of lung disease (RR=1.53, p<0.0001). Likewise, survival analysis of HD and PD 
patients with the presence of CHF in Taiwan showed that chronic lung disease at the baseline 
was significantly associated with mortality (HR=1.09, p=0.17) (Wang et al., 2013). In contrast to 
these findings, some studies found the insignificant of lung disease on survival outcome. For 
example, a very recent multicenter prospective cohort study in Korea by Park et al. (2018), 
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demonstrated the non-significant impact of chronic lung disease history on survival among 
Korean dialysis population (HR=1.24, p=0.2). Similarly, survival outcome comparison between 
HD and PD patients in France revealed that presence of chronic lung disease did not impact the 
survival (HR=1.09, p=0.17) (Sens et al., 2011).  
2.8.4. Mental health disorders 
Several investigators showed that poor mental health at the time of starting dialysis can 
impact survival of dialysis patients. For instance, depression as the most common type of 
psychological disorder in dialysis patients is associated with a high risk of mortality in this 
population (Fischer, Porter & Lash, 2013). Chilcot et al., in 2010 analyzed 160 incident HD and 
PD patients from three renal centers in the UK in a prospective study. Using Cox regression 
model adjusted for other comorbid conditions illustrated that depression score was a significant 
predictor of mortality (HR=1.07, p=0.002). Moreover, in an additional adjusted Cox model, the 
severity of depression symptoms soon after the dialysis initiation was also an independent 
predictor of survival outcome (Chilcot et al., 2010). In another prospective study in Southwestern 
Pennsylvania survival analysis of 66 PD patients revealed that depressive patients experienced a 
higher risk of death (Einwohner, Bernardini, Fried, & Piraino, 2004). Examination of different 
factors such as psychiatric disorders, including dementia, depression and bipolar and their 
association with survival outcome was conducted by Goodkin et al., in 2003 among HD patients. 
Analyzing DOPPS registry data as an observational prospective study indicated significant 
impact these psychiatric disorders on survival outcome in both multivariate and univariate 
analysis (univariate: RR=1.64, p<0.0001; multivariate: RR=1.3, p<0.0001).  
  
31 
A retrospective cohort study analyzing 272, 024 incident dialysis patients in the United States 
Renal Data System (USRDS), estimated the risk of death among those diagnosed with dementia 
at the baseline. Using Cox regression model showed that presence of dementia at the time of 
commencing dialysis is an independent risk factor for mortality (HR=1.91, p<0.001) (Rakowski, 
Caillard, Agodoa & Abbott, 2006). Another large registry-based study using DOPPS data  also 
highlighted the significant impact of dementia on adverse outcome among HD patients 
(RR=2.01, 95% CI=1.57-2.57) (Kurella, Mapes, Port & Chertow, 2006).  
In spite of significant findings on the impact of mental health factors on survival of dialysis 
patients, there are some early studies that found an insignificant association of these factors and 
the survival outcome. For instance, analyzing 97 HHD and PD patients revealed that existence of 
depressive symptoms was not associated with survival outcome (Devins et al., 1990). Similarly, 
survival analysis of 295 incident HD dialysis patients in a prospective, longitudinal study 
indicated the non-significant impact of depression on mortality (Kimmel et al., 1998).   
Some other further studies also showed this insignificant association of depression and 
mortality in dialysis population such as studies by Kimmel et al. in 2000 and Boulware et al. in 
2006. Additionally, comprehensive examination of depressive symptoms and their impact on 
mortality among 323 HD patients by Fan et al. (2014), revealed the attenuated association 
adjusted for other comorbidities.  
2.8.5. Physiology indicators 
Laboratory values such as albumin, hemoglobin, potassium and phosphorus are among the 
important determinatives for mortality not only at the time of commencing dialysis but also 
during the course of maintenance dialysis. In an observational study analysing chronic dialysis 
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patients’ data over 14 years, laboratory values within three to six months after dialysis initiation 
whether HD or PD were considered. The impact of albumin, serum phosphate, and calcium on 
long-term survival outcome were explored retrospectively. By grouping patients into two 
different groups based on the threshold value of serum phosphorus (above and below 1.8 
mmol/L), only18 percent of the patients had the value above this level. The results of the study 
indicated that the five-year survival of these patients was 48.4% compared to those with a serum 
phosphorous<1.8 mmol/L with the survival rate of 58.6%. For albumin, five-year survival was 
65.1% for patients that have the value of above 35 g/L versus 37.7% for those with the value 
below the threshold (p<0.001, 95%CI=0.98-1.25). In brief, hypoalbuminemia and 
hyperphosphatemia were strong predictors of all-cause mortality in this study. It was also 
concluded that low serum albumin along with other factors such as low BMI and low blood 
nitrogen urea, are considered as signs of under-nutrition leading to reduced survival (Phelan, 
O'Kelly, Walshe & Conlon, 2008).  
In a retrospective observational study by Mafra et al. (2007) in a five-year follow-up, the 
effect of low BMI and serum albumin on increased risk of mortality were examined using a Cox 
model (86). In the analysis, two categories of patients in terms of level of albumin were defined 
(below and above 3.5 mg/dl). The results of the study showed that lower levels of 
BMI(<19kg/M2) and albumin (<3.5 mg/dl) are the most significant predictors of increased risk 
of mortality among hemodialysis patients. The risk of all-cause mortality was 2.63 times higher 
in the category of lower albumin (p<0.001, 95%CI=01.05-1.25) and 1 g/l increase in serum 
albumin was associated with improved survival which was significantly reduced hazard of 
mortality (HR= 0.97, p<0.001) (Mafra et al., 2007). Similarly, in a retrospective descriptive 
study, the impact of BMI and albumin were evaluated among 204 African-American 
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hemodialysis patients. The research demonstrated that albumin<3.2 g/dl is one of the strong 
predictors of mortality. Using the mean value of albumin in the logistic regression model 
demonstrated that significant impact of it on survival (p<0.001, 95%CI=1.06-1.35) (Feingold, 
Adams, Penprase & Tubie, 2007). 
The findings of the aforementioned studies were consistent with Bradbury et al. (2007) and 
Kalantar-Zadeh et al. (2005) surveys indicating that low albumin level is one of the powerful risk 
factors for mortality in HD patients. In the first study, a retrospective cohort from DOPPS in US 
were used to explore the most significant predictors affecting survival. Preliminary analysis of 
the first study demonstrated that 40% of the patients had albumin below 3.5 g/dl (Bradbury et al., 
2007). In the second study, all-cause and CV mortality was highly influenced by a decline in 
serum albumin over the course of six months. For the same duration, improved survival outcome 
was correlated with increased level of serum albumin of >= 0.3 g/dl with HR=0.78; 95%CI= 
0.71-0.86 (Kalantar-Zadeh et al., 2005).  
More recently for peritoneal dialysis patients, the impact of albumin on mortality was 
assessed in a prospective, single cohort of 30 patients over five years by Terawaki et al. in 2012. 
In this study, the correlation of serum albumin and incidence of serious CVD was examined. The 
results of this study revealed that a lower level of reduced albumin is significantly correlated 
with serious incidence of CVD and corresponding mortality (Terawaki et al., 2012). 
As mentioned before, survival outcome is also influenced by different physiology indicators 
such as hemoglobin and phosphorus as equally important variables. Hyperphosphatemia, control, 
is considered as one of the important integrals of chronic kidney disease management. 
Kestenbaum et al. (2005) demonstrated that elevated serum phosphorus is significantly 
associated with increased risk of mortality. Similarly, another study indicated that decrease in 
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serum phosphorus in patients with baseline values of > 5.2 mg/dL is correlated with improved 
survival outcome (Fernández-Martín et al., 2015). However, two studies conducted by Tentori et 
al. (2007) and Thijssen et al. (2012) respectively, found insignificant impact of phosphorous on 
mortality compared to other laboratory predictors. In the study by Thijssen et al. (2012), the 
hemoglobin levels after initiation of HD was significantly associated with mortality. In 
accordance with these findings, a study from UK Renal National Registry cohort, indicated that 
hemoglobin is one of the powerful predictors of mortality (Wagner et al., 2011).  
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 Chapter 3: Study rationale and research questions 
 
3.1. Clinical and public health implications 
High mortality is reported among dialysis patients, particularly within the first months after 
dialysis initiation. According to Bradbury et al. (2007), 20% of the total deaths occur in the first 
year after dialysis initiation. This high rate of mortality and the corresponding reasons have 
drawn great attention from physicians and clinical researchers worldwide. However, the reasons 
for this high rate still remain unclear and require full exploration. 
 The overall aim of this study was to (1) estimate the survival rate of incident chronic 
dialysis patients in the regional renal program at Grand River Hospital (GRH), (2) determine 
whether the survival outcome differed in Hemodialysis (HD) and Peritoneal Dialysis (PD) 
patients and, (3) identify significant variables that affect survival outcome.  
The essential knowledge gained through this investigation is intended to help dialysis 
patients enhancing individual outcome by improving modifiable risk factors. Moreover, the 
results of this study will contribute to future planning and organizing of renal dialysis programs 
such as the Ontario Renal Network (ORN) and British Columbia Renal Agency (BCRA). Based 
on the knowledge extracted about differences between patients who survived and those who did 
not during the same period, physicians and clinical teams may be better able to predict potential 
problems before they arise. Extracted prognostic information will help patients share in their 
treatment decisions rather than having them dictated.  
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3.2. Research questions and objectives 
3.2.1. Primary research questions 
1) What is the current survival rate among dialysis patients receiving care in GRH? 
2) Does the survival outcome differ for patients receiving HD and PD? 
3) What are the significant predictors for the survival outcome of chronic dialysis patients? 
3.2.2. Study objectives 
The objectives of the proposed study are to investigate the following in a retrospective cohort of 
chronic dialysis patients in GRH: 
a) The overall survival rates, by: 
• Age group, gender, and type of modality 
b) Whether the survival outcome differs among patients undergoing PD and HD. 
c) The significant predictors that affect survival outcome. 
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 Chapter 4: Methods 
4.1. Data source 
The Ontario Renal Network (ORN) consists of 26 regional renal programs, each offering a 
variety of treatment services to patients suffering from Chronic Kidney Disease (CKD) in 
Ontario. Grand River Hospital’s (GRH) renal program, recognized as one of the largest 
community hospital regional dialysis programs (i.e., the eighth largest program) in Ontario, 
provides acute and chronic kidney disease services within Waterloo Wellington. This renal 
program includes in-center, home and satellite Hemodialysis (HD) units, as well as out-patient 
Peritoneal Dialysis (PD) and chronic kidney disease clinics. To demonstrate, these services 
consist of “early identification, delay of disease progression, inpatient dialysis, (home HD and 
PD), modality selection, acute HD and pre-transplant preparation” (Waterloo Wellington 
Regional Renal Program, Renal Plan 2015-2019)1. Satellite units in this renal program provide 
services for patients in Kitchener, Guelph and Palmerston regions. There are 74 HD stations 
available in the Waterloo Wellington regional program. In total, over 500 patients receive 
dialysis and more than 140 home-based dialysis patients live independently in this regional renal 
program.  
 
4.2.  Study population 
Inclusion criteria: Male and female adult patients (>18 years old) who began chronic 
dialysis treatment (at home or hospital) between January 1th, 2012 and September 30th, 2017 in 
                                                
1 Waterloo Ellington Regional Renal Program, Renal Plan 2015-2019. CCO. Ontario Renal Network. Retrieved at: 
http://www.grhosp.on.ca/assets/documents/GRH-renal-plan.pdf 
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the renal program at Grand River Hospital were eligible for the analysis. Patients who underwent 
dialysis for more than 30 days were considered chronic. This definition is extracted from ORN 
definition1 (Lattouf & Ricketts, 1986).  
Exclusion criteria: In this study, patients who started dialysis on an emergency basis or 
acute dialysis (with the duration from first to last dialysis being less than 30 days) and those 
having only one dialysis session were excluded. An exception was applied to those 
discharged/recovered or withdraw from treatment, but who later started chronic dialysis. For this 
group, the first day of dialysis was estimated from the initiation of chronic dialysis. In order to 
prevent lead time bias, patients who were undergoing dialysis before the study’s start date (i.e., 
prevalent patients) were excluded from the study. 
4.3. Ethics 
Ethics approval was obtained from the Human Research Ethics Board of the University of 
Waterloo (ORE # 22069). The study was also approved at the GRH by the Tri-Hospital Research 
Ethics Board (THREB) (THREB File # 2016-0619), along with the waiver of “the requirement 
to obtain patient informed consent”. The ethics approval forms can be found in the Appendix E.  
4.4. Data extraction 
Patient-information reporting platforms, including Nephroport and Nephrocare for the renal 
program at GRH, as well as clinical chart reviews of participants’ electronic files in 
ClinicalConnect™ were utilized for data extraction. All the required Protected Health 
Information (PHI) protection measurements were applied strictly during data extraction, to 
ensure appropriate access control to databases and the crosswalk file. Medical Record Numbers 
                                                
1 Ontario Renal Network (ORN)- Ontario Renal Plan. Retrieved at: 
http://www.renalnetwork.on.ca/ckd_data/accountability_to_patients_data/techinfo/ - .W1Yw2K0ZP-Z 
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(MRNs) were used to identify relevant patient records and were identified on the data collection 
forms as Subject Identification Numbers (Subject_IDs). Random Subject_IDs and Encounter 
Identification Numbers (E_IDs) were generated to identify each patient and encounter. Final 
mapping information across Subject_IDs, MRNs and E_IDs in the crosswalk file were stored on 
a secure computer in GRH.  
De-identified extracted data were entered in Excel sheets for the analysis. Two graduate 
students checked the validity of extracted data by randomly selecting patients and comparing the 
values across Nephrocare, ClinicalConnect™, and the extracted data file. Preliminary descriptive 
analysis in two separate analyses conducted, by the same two graduate students, also cross-
validated the extracted data file. Furthermore, each patient’s clinical records and notes in the 
ClinicalConnect™ were reviewed.  
4.5. Data collection steps  
In the first step, data for the included variables were extracted from the two patient-
information platforms in the renal program at GRH. This step lasted from February 2017 to May 
2017. Subsequently, between June and October 2017, the same students reviewed each patient’s 
record in Nephrocare in order to check for the validation and completeness of the extracted data. 
All the variables included in this study were recorded in an Excel file. For validation and data 
entry quality assurance, a few patients were randomly selected and checked. In the next step, 
missing values for selected variables were completed by having three graduate students review 
clinical notes and reports available in ClinicalConnect™. A mixture of clinical notes, assessment 
summary and history summaries were available in the ClinicalConnect™ for each patient. To 
review the most relevant reports, several strategies were adopted such as selecting reports close 
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to dialysis initiation and using nephrologists’ assessments, discharge summaries and 
anesthesiologist summaries.  
For reviewing the clinical notes in the last step, a few assumptions were made for the 
purpose of quality control assurance. For recording comorbidities, the presence of any diagnosis 
identified by the clinicians at the dialysis initiation was selected and used as a comorbidity, 
whether the patient recovered or the disease improved subsequently.  
 
4.6. Key variables in survival analysis: 
a) Outcome variable:   
The outcome variable can be represented by pairs of random variables as (T, δ).  In 
survival analysis, the primary outcome variable is “time until an event occurs”, denoted 
by T (Kleinbaum & Klein, 2006). The status variable, δ, indicates either the occurrence of 
an event or censorship for the patient. Where δ=1, the patient experienced the event of 
interest during the study period, while δ=0 means that the survival time was censored in 
the study period (Dietz at al., 2002). In fact, if the event did not occur during the follow-
up time, the censorship was the only possibility for the patient’s survival time (lost to 
follow-up or survived until the study end point). In this study, the starting point was 
defined as the time of dialysis therapy initiation, based on the date of patients’ first 
recorded dialysis treatment. Thus, the outcome variable was measured from the dialysis 
initiation until death. Patients who were lost to follow-up, transferred out of the hospital 
or to another center, transplanted or remained in the study to the end of study period were 
right-censored. It was assumed that censoring was independent or non-informative in this 
study. 
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b) Independent variables: 
Based on the retrospective nature of the study and the availability of the variables, as well 
as on the results of the literature review on significant predictors in survival, the 
following variables were chosen: 
1) Age at dialysis initiation in years: measured from birth year at the time of starting 
dialysis. Age is considered as a confounder in this study as it may affect the association 
between various comorbidities and survival outcome.  
2) Gender (male/female): 1=Male, 2=Female. 
3) Myocardial Infarction (MI): (1= Yes, 0=No) 
4) Cardiac disease, including Coronary Artery Disease (CAD), cardiac arrhythmia, cardiac 
failure, cardiac valvular disease, pericardial disease, cardiomyopathy, and congenital 
heart disease: (1= Yes, 0=No) 
5) Cerebrovascular Accident (CVA): (1= Yes, 0=No) 
6) Cancer: (1= Yes, 0=No) 
7) Lung disease: (1= Yes, 0=No) 
8) Diabetes: (1= Yes, 0=No). 
9) Hypertension (HTN): (1= Yes, 0=No) 
10) Depression: (1= Yes, 0=No) 
11) Bipolar: (1= Yes, 0=No) 
12) Dementia: (1= Yes, 0=No) 
13) Modality: type of modality 90 days after dialysis initiation (HD=1, PD=2) 
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It is worth mentioning that although laboratory values were collected for this study, they 
were not included in the statistical analysis. The reason is that laboratory values available in the 
systems were not necessarily captured exactly at the time of dialysis initiation and there was a 
possibility that those values had been improved by starting the dialysis therapy. 
4.7. Statistical analysis 
Prior to the survival analysis, long data format was converted into wide format using R 
statistical software. A value of p<0.05 was considered statistically significant. All statistical 
analysis was conducted in R statistical software. The statistical methods used in this study are 
described below. 
4.7.1. Descriptive data analysis  
To describe and summarize the baseline characteristics of the study, descriptive analysis was 
performed. The frequency distributions of patients, central tendency, and dispersion were 
evaluated. For categorical variables, frequency and percentage were used, and continuous 
variables were presented as the mean and standard deviation (SD) (i.e., mean±SD). Along with a 
general description of the cohort, patient characteristics according to the age and the type of 
modality were compared, using the Chi-square test for categorical variables and t-test for 
continuous ones. For both tests, a two-sided p of 0.05 was used to denote the significance of 
comparing the HD and PD groups.  
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4.7.2. Kaplan-Meier survival curves  
In order to analyze unadjusted survival, Kaplan-Meier (KM) survival curves were employed 
for different age groups, genders and types of modality. For the whole cohort, the overall 
survival curves were also generated. As a description of survival time in this cohort, the median 
survival time and probability of survival were estimated. The KM analysis is described next.    
 KM is one the most common estimators that deals with survival data and can be used for 
preliminary descriptive analysis such as median survival time calculation, as well as in creating 
survival curves (Bruce, Pope & Stanistreet, 2008). Information from all the observed subjects, 
including censored and uncensored can contribute to the KM estimator by representing any time 
point as a series of steps identified by the observed survival and censored times (Smith & Smith, 
2003). Of note, this method is suitable when there is no assumption regarding the hazard rate 
(i.e., no assumption about the functional distribution of hazard rate with time).  Both the median 
survival time and the proportion of subjects alive at a specified time can be extracted directly 
from the KM graph (Allison, 2010).  
The KM estimator is as following:  
! " = 1 − &'('':*+,* 1  
 
where dj is the number of individuals who experienced the event of interest at time tj, and nj is 
the number of individuals who are at risk at the time of experiencing the event (since they have 
not yet experienced the event by that time) (Smith, T., & Smith, B., 2003). 
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4.7.3. Log-rank test 
This statistical test was used to compare the survival time of one or more groups for the 
variables, including age, gender and modality type. One of the most popular methods used for 
evaluating whether or not KM curves are statistically different for one or more groups is the log- 
rank test. It is a form of large-sample chi-square statistical test that evaluates a null hypothesis. 
Under this hypothesis, it is assumed that “there is no difference between populations in the 
probability of an event at any time” (Singh & Mukhopadhyay, 2011).  
To perform this statistical test, in each group, the number of observed events for each single 
time point and the number of expected events (number of individuals who are at risk at a given 
time point multiplied by the number of events at the given time point) is required. The log-rank 
test formula for more than two groups is as follows (Kleinbaum & Klein, 2006): 
-. = /0 − 10 .1020 2  
where Oi is the total number of observed events (i.e., death), Ei is the expected number of 
events, and n is the number of groups.  
The degree of freedom for this statistical test in large sample sizes is G-1, where G is the 
number of groups being compared. The p-value for this statistical test is obtained from chi-
square distribution tables (Kleinbaum & Klein, 2006).  
4.7.4. Modeling survival data 
The modeling of survival data is important for two main reasons: 1) to identify which 
combination of potential explanatory variables affect the hazard functions; 2) at the individual 
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scale, to estimate the hazard function for each patient. This estimation leads to obtaining 
quantities such as the median survival time, which will be a function of the explanatory variables 
in the survival model. For future and current patients, with particular values of the explanatory 
variables, the median survival rate can be estimated. Therefore, the resulting estimation could be 
useful in counseling patients’ about their prognoses, as well as in customizing treatment plans for 
patients with different characteristics. Two fundamental functions are used to summarize and 
model the survival data: the survival function and hazard function. 
4.7.4.1. Survival function:  
Obtaining survival probabilities from different values of t provides important information 
from survival data. The survival function (or reliability function) denoted by S(t) gives the 
probability that an individual will survive beyond a certain point of time, t (experience the event 
of interest after time t).  ! " = 	5 6 > " (3) 
T refers to a nonnegative random variable denoting the time to an event or the survival time.  
Since T is a continuous variable, the survival function is the complement of the cumulative 
distribution function, which is:  ! " = 	1 − 	; " 4  
where F(t) = P (T ≤ t). 
Thus, the survival function is the integral of the probability density function, which is f(t). 
The survival function can be written as follows (Therneau & Grambsch, 2013): 
! " = 5 6 > " = 	1 − 	; " = = " &">* 5  
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4.7.4.2. Hazard function  
Survival models are often written in terms of a hazard function, which is considered as 
another quantity fundamental to a survival analysis context. This function is defined as follows, 
where Δt denotes a small interval of time. The formula for the hazard function is 
ℎ " = ABCD*→F 5 " ≤ 6 < " + J" 6 ≥ "J" 6  
While the survival function only gives a cumulative measure over time, a hazard function 
reveals a measure of instantaneous potential at time t for the event to occur, given that the 
individual has survived up to time t (Therneau & Grambsch, 2013). Unlike the survival function, 
which focuses on not failing, the hazard function focuses on failure, which is the event occurring. 
4.7.5. Multivariate analysis 
The above-mentioned statistical analyses (i.e., Kaplan-Meier and log-rank test) methods 
were utilized to investigate survival outcome with respect to one factor under investigation. 
Primarily because these methods consider only one dependent variable at a given time, the 
association among more than one variable in a multivariate method would be explored. Hence, a 
multivariate Cox proportional hazard regression was generated to determine which combination 
of potential explanatory variables affects the form of hazard function. This analysis was very 
informative because it evaluated multiple variables. For example, this model yielded the hazard 
ratio that gives the effect of each variable adjusted for age as a confounder in the model. In the 
following, there is a statistical description of the Cox model: 
     In order to model the time to an event, non-parametric and semi-parametric survival analysis 
techniques are often used. The Cox proportional hazard Model, a semi-parametric model, is 
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preferred over logistic models in the presence of censoring and survival data, as a logistic model 
ignores survival times by considering only a (0,1) as an outcome whereas the Cox model uses 
survival information (Kleinbaum & Klein, 2006). The Cox model specifics the survival function 
predicting the probability of an event at a given time t for given values of the predictors. This 
analytical method enables us to model how the risk of death depends on a number of predictors 
or explanatory variables. Categorical and continuous variables, either alone or in combination, 
are handled readily in a Cox regression model (Bruce at al., 2008). It is much more useful to 
employ Cox models when there are continuous variables, rather than the Kaplan-Meier approach. 
Cox regression coefficients and survival function shape are identified by the cohort subjects 
(observed subjects) (Therneau & Grambsch, 2013). The produced model can be applied to new 
patients who have measurements for the explanatory variables. The Cox model is usually written 
in terms of hazard function. The Cox proportional model identifies the hazard at time t for an 
individual with a given set of explanatory variables which follows (Kleinbaum & Klein, 2006): 
ℎ ", x = ℎF " exp Q0-020RS 7  
 
where ℎF "  is the baseline hazard function (or nonnegative function of time), b is a regression 
coefficient, U = (-S, -., … , -2) denotes the vector of explanatory variables.  
4.7.6. Variable selection 
In statistics, particularly in regression analysis with a number of variables, not all variables 
may contribute to the response. Consequently, sometimes it is desirable to reduce the number of 
variables included in the final model. The purpose of variable selection is to improve model 
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prediction accuracy and also to make it easier to interpret (Dietz et al., 2002). In this study, a 
backward selection variable procedure was performed using R statistical software.  
The initial Cox model started with all 13 variables included in the model, and at each step, 
the least significant variable (i.e., variable with the largest p-value) was removed from the model. 
This procedure continued until the p-values were below the critical p-value (Moore & Dirk, 
2016).  
4.7.7. Assumption of proportional hazard 
In this study, one of the issues which needed to be assessed was the assumption of 
proportional hazard. The key assumption of the multiplicative hazard models is that the ratio of 
hazard for a given variable does not change over time. The hazard for each subject is a fixed 
proportion of hazards, meaning that the effect of a given explanatory variable is constant over 
time for all other subjects in a group (Hess, 1995). In other words, when all the explanatory 
variables are fixed at time 0, the hazard ratio of two subjects or individuals with the value of xi is 
proportional (Dietz at al., 2002). In fact, the relative hazard for any two subjects follows this 
relationship (Therneau & Grambsch, 2013): ℎF " WXYZℎF " WX+Z = WXYZWX[Z 8  
This relationship is independent of time and holds different subjects (i.e., i and j) for each 
variable.  
In this study, the proportionality assumption was assessed using a Schoenfeld statistical test. 
This method is the most preferred and reliable one compared to other techniques such as 
graphical ones, because it uses a statistical method and provides a statistical test and a p-value 
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for a given explanatory variable (Kleinbaum & Klein, 2006). This test, originally proposed by 
Schoenfeld in 1982, has three main steps for implementing this statistical test. In the first step, a 
Schoenfeld residual for each variable in the model is calculated. Then, survival times are ranked 
by creating a variable (Kleinbaum & Klein, 2006). Finally, the correlation between the variables 
created in the first step and the ranked ones is tested in the H0 hypothesis. Rejection of the null 
hypothesis indicates that proportionality is not satisfied. (Kleinbaum & Klein, 2006).  
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 Chapter 5: Results 
5.1. Dataset 
A total of 723 chronic dialysis patients who started dialysis between January 1, 2012 and 
September 30, 2017 were included in the current analysis. During this period, death occurred in 
284 patients (39.28%). Of the whole cohort, 18.4% (n=133), 9.7% (n=70), 5.5% (n=40), 4.1% 
(n=30), 1.1% (n=8) died in the first year, second year, third year, fourth year, and fifth year, 
respectively, during that period. The average follow-up time was 644 days. Of the whole 
deceased patients, 70 were voluntarily withdrawal patients who were also considered deceased in 
consulting with the clinical experts and the existing palliative care protocol in GRH. Any death 
that occurred after the study cut-off date of September 30, 2017 was censored.  
5.2. Descriptive analysis  
Descriptive analysis was conducted to describe the population characteristics during the 
study duration. Table 1 presents the descriptive characteristics of the full dataset (n=723) and 
Table 3 presents them by type of modality. Overall, most of the included patients were males 
(62.66%), aged on average 64.86 years old at the time of dialysis initiation. More than half were 
located in the two older age categories (28.77% being 65-74 years old and 28.63% being more 
than 75 years old). The two youngest groups of patients contained the least number of dialysis 
patients, with only 10.93% and 10.51% in the categories 18-44 and 45-54 years old, respectively. 
Patients aged 55 to 64 had the frequency of 21.16% of the whole cohort. Therefore, most of the 
patients were relatively old at the time of dialysis initiation.  
A majority of the patients (81.88%) initially underwent HD, and the rest started PD 
(18.12%). The comorbid conditions at baseline, in the order of most-to-least common, were HTN 
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(88.8%), diabetes (63.76 %), cardiac disease (57.12%), cancer (31.54), MI (27.39%), CVA 
(27.11%), and lung disease (23.79%). This dataset was a healthy group of individuals in terms of 
psychological indicators. To demonstrate, only 5.53% had dementia, 2.49% had bipolar disorder, 
and 29.46% had depression.  
Table 1. Descriptive characteristics of analytic sample (N=723) 
Variable Frequency (n) Percentage 
Age (Mean±SD) (64.86±14.89) 
    18-44 79 10.93 
    45-54 76 10.51 
    55-64 153 21.16 
    65-74 208 28.77 
    >75 207 28.63 
Gender 
     Male  453 62.66 
     Female 270 37.34 
Modality 
     HD 592 81.88 
     PD 131 18.12 
Comorbidities 
     Diabetes 461 63.76 
     HTN 642 88.8 
     Cardiac disease 413 57.12 
     MI 198 27.39 
     Cancer 228 31.54 
     CVA 196 27.11 
     Lung disease 172 23.79 
Mental health disorders   
    Dementia 40 5.53 
    Depression 213 29.46 
    Bipolar 18 2.49 
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5.3. Baseline characteristics by age  
Age was considered as the confounder in the current analysis, to describe the effect of 
different risk factors on survival outcome. Thus, it is important to estimate the impact of age on 
variables included in this study. Table 2 lists average age and Standard Deviation (SD) estimates 
for the variables used in describing the study cohort. Male and female patients had a similar 
average age (males: 65.11, females: 64.43, p=0.56). As shown below, patients without 
comorbidities and mental disorders were generally younger than those with such risk factors, 
apart from depression, bipolar and HTN. However, this association was not statistically 
significant for some of the variables such as CVA (yes: 65.91, no=64.46, p=0.24) and diabetes 
(yes: 65.62, no=63.52, p=0.08). The average age was strongly associated with five variables, in 
that patients without MI (yes:67.95, no:63.69, p<0.001), cardiac disease (yes:67.85, no:60.87, 
p<0.001), dementia (yes:74.7, no:64.28, p<0.001), lung disease (yes:68.09, no:63.85, p<0.001) 
and cancer (yes:66.57, no:64.07, p=0.03) were younger. Notably, bipolar (yes:51.89, no:65.19, 
p=0.01) and depression (yes:62.54, no:65.83, p=0.01) were also significantly associated with age 
but in a reverse way as patients with these risk factors were younger. In summary, all mental 
health disorders were significantly associated with age, while only four comorbidities were 
significantly associated with age. It is worth mentioning that descriptive results based on mental 
health disorders, may prone to underreporting issues practically among younger group of 
patients.    
 
 
 
 
  
53 
 
Table 2. Baseline characteristics by age 
Variable  Average age  SD P-value 
Gender    
     Male  65.11 14.43 0.56 
     Female 64.43 15.66 
Modality    
     HD 64.93 14.80 0.784 
     PD 64.52 15.34  
Comorbidities    
     HTN    
        Yes 
        No 
64.70 
66.10 
14.93 
14.60 0.42 
     Cardiac disease    
        Yes                     67.85 12.66 <0.001** 
        No 60.87 16.63 
     CVA    
         Yes 65.91 14.71 0.24 
         No 64.46 14.95 
      MI    
        Yes 67.95 11.64 <0.001** 
         No 63.69 15.80 
      Diabetes    
        Yes 65.62 13.78 0.08 
        No 63.52 16.62 
      Cancer    
        Yes 66.57 13.27 0.03* 
        No 64.07 15.53 
      Lung disease    
        Yes 68.09 11.96 <0.001** 
        No 63.85 68.09 
Mental health disorders    
      Depression    
        Yes 62.54 14.5 0.01* 
        No 65.83 14.96 
      Bipolar 
 
 
 
        Yes 51.89 19.48 0.01* 
        No 65.19 14.62 
      Dementia    
        Yes 74.7 11.63 <0.001** 
        No 64.28 14.87 
Asterisks denote difference between groups; *significant at 0.05 level; **significant at 0.001 level 
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5.4. Baseline characteristics by type of modality 
Prevalence estimates for HD and PD modalities were calculated within the entire chronic 
dialysis patient sample (n=723). As shown in Table 3, patients in both the PD and HD groups 
were further subdivided using the variables included in the study: age, gender, cardiac disease, 
HTN, diabetes, CVA, MI, dementia, depression, bipolar, cancer and lung disease. HD and PD 
patients did not significantly differ in terms of age at the time of dialysis initiation. In general, 
both groups of patients had a similar average age at the baseline (HD patients: 64.93, PD 
patients: 64.52, p= 0.784). Frequency of male and female patients in HD and PD modalities was 
also similar (males; HD patients: 63.5%, PD patients: 58.8%, p-value=0.361). 
  The comparison of baseline characteristics among the entire study cohort according to the 
type of modality revealed significant differences in cancer, diabetes and lung disease 
comorbidities. The prevalence of diabetes mellitus was significantly higher in PD patients than in 
HD patients (PD patients: 71.8%, HD patients: 62%, p = 0.045). In contrast, the number of HD 
patients with lung disease (PD patients: 16%, HD patients: 25%, p = 0.028) and cancer (PD 
patients: 22.1%, HD patients: 33.2%, p = 0.014) was significantly higher than the group of PD 
patients. 
No significant differences existed between the two patients group (HD/PD) for HTN (HD 
patients: 88%, PD patients: 92%, p = 0.201), cardiac disease (HD patients: 57.3%, PD patients: 
56.5%, p = 0.949), CVA (HD patients: 26.4%, PD patients: 30.5%, p = 0.287) and MI (HD 
patients: 27.7%, PD patients: 26%, p = 0.766).  
HD and PD patients did not differ in respect of psychological indicators, such as bipolar 
(HD patients: 2.2%, PD patients: 3.8%, p = 0.443), and depression (HD patients: 29.2%, PD 
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patients: 30.5%, p = 0.848). There was a tendency for HD patients to suffer from dementia more 
frequently than PD patients, but these differences did not reach statistical significance (HD 
patients: 6.3%, PD patients: 2.3%, p = 0.114).  
Figure 4 illustrates the modality distribution based on the defined five age categories. As 
expected from the overall distribution of HD and PD modalities, frequency of HD is higher in all 
age categories. Distribution of PD is roughly similar in all groups and only ranges from 16% to 
22%. PD is most common in the group of 55-64 years old with 22% and least common in the 
group of 65-74%. Similarly, HD distribution is roughly similar in different age categories.  
 
 
 
Figure 4. Modality distribution by age categories 
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Table 3. Baseline characteristics by dialysis modality 
Characteristics HD PD P-value 
  Frequency Percentage  Frequency Percentage   
Age at dialysis initiation 
(Mean±SD) 64.93±14.8 64.52±15.34 
0.784 
Gender    
          Male 376 63.5 77 58.8 0.361 
          Female 216 36.5 54 41.2 
Comorbidities   
          Diabetes 367 62 94 71.8 0.045* 
          HTN 521 88 121 92.4 0.201 
          Cardiac disease 339 57.3 74 56.5 0.949 
          MI 164 27.7 34 26 0.766 
         CVA 156 26.4 40 30.5 0.387 
         Lung disease 151 25.5 21 16 0.028* 
         Cancer 199 33.6 29 22.1 0.014* 
Mental health disorders    
        Dementia 37 6.3 3 2.3 0.114 
        Bipolar 13 2.2 5 3.8 0.443 
        Depression 173 29.2 40 30.5 0.848 
Asterisks denote difference between HD and PD; *significant at 0.05 level; **significant at 0.001 level 
 
 
5.5. Kaplan-Meier (KM) survival curves  
KM survival curves were generated to show the cumulative survival of the entire cohort 
during the study. Survival curves were stratified by important factors such as different age 
groups, gender and type of modality, to visualize the survival experience of dialysis patients in 
GRH. The KM survival curve estimating the overall survival of the incident chronic dialysis 
population during the study period is presented in Figure 5.  
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In Figure 5, the survival function has been graphed over the study follow-up time. There 
is a constant decrease in survival function during the study period as it started at 1 and went 
down in a decreasing direction to 0.27. A rise in the survival time of dialysis patients 
corresponds to a drop in their cumulative survival rate. The KM cumulative survival curve is 
surrounded by the 95% confidence intervals. The corresponding confidence intervals were 
relatively narrow, indicating the considerable reliability of the cumulative survival estimates.  
The median survival time for all 723 patients was 39.8 months, which is the smallest 
survival time point for which the cumulative survival is less than or equal 50%. As shown in 
Figure 5, the 1-, 2-, 3-, 4- and 5-year survival rates for the incident chronic dialysis patients in 
GRH were estimated to be 0.80, 0.65, 0.54, 0.41 and 0.34, respectively.  
 
 
Figure 5. KM survival curve for all chronic dialysis patients (solid line) and the corresponding 
CI (dashed lines) 
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5.5.1. KM curves for different age categories  
Figure 6 represents the KM curve for survival of the cohort, stratified by age categories. 
Corresponding age categorization was extracted from the CORR national renal registry (2017) in 
order to compare the survival rates for GRH. All the survival probabilities for all age groups start 
at a survival probability of 1 and step down to the other survival probabilities. These five age 
groups of patients appear to be quite different, as all of curves increasingly diverge over time.  
As the graph demonstrates, the estimated survival probability for the youngest group of 
patients (18-44 years old) consistently lies above that of all other groups. This difference 
indicates that the youngest group of dialysis patients in GRH had a greater survival probability at 
all points of follow-up. The two youngest groups of patients (18-44 and 45-54 years old) are 
somewhat closer together in the first 42 months of the study duration. After this point, the two 
curves diverge slightly, then maintain a consistent distance apart until the study end.  
For two groups of patients: 65-74, and older than 75 years old, Figure 6 shows a quick 
drop in survival probability in the 12 months of follow-up. During the first year of follow-up, 
these two groups experienced quite similar survival, but thereafter the survival probabilities start 
to diverge notably, a trend that continues until to the end of the study. The 65-74 group has a 
higher survival probability after the first twelve months of the study compared to the older group. 
Similar to the other groups, patients aged between 55 to 64 years old, had a constant decrease in 
survival probabilities during the study follow-up. The difference between this group and patients 
aged 65 to 74 years old is about the same over time except in the middle of the study period in 
which two curves converge a bit. Roughly, this difference remained the same until the end of the 
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study. In summary, as the number of months increases, the five age groups’ KM survival curves 
appear to get farther apart, suggesting the beneficial impact of younger age over older groups.  
 
 
Figure 6. KM survival curve for chronic dialysis patients by age categories  
 
In order to compare the survival of different groups, a log-rank test was conducted, 
providing a comparison of the overall survival experience of different age categories. Comparing 
the survival for the five different age categories reveals that the equality of survival functions 
had a p-value of less than 0.05, confirming that the survival probability of the five age categories 
significantly differed (Table 4 and Appendix F). Therefore, the null hypothesis that all five 
survival curves would be the same was rejected.  
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Table 4. Log-rank test for baseline age categories 
		  Number of patients Number of deaths 5-year survival rate 
Age      
       18-44 80 8 0.85 
       45-54 78 11 0.77 
       55-64 156 56 0.38 
       65-74 227 98 0.29 
        >75 217 134 0.09 
                                Log-rank test: p< 0.001  
 
5.5.2. KM curves for gender  
Figure 7 is the KM curve for survival of the cohort stratified by gender. Survival 
probabilities appeared best for women during the first 48 months of the study. The KM curves 
initially separated with a higher survival probability for women until about 48 months of study 
follow-up.  The survival probabilities of men and women converged as the KM survival curves 
crossed at 48 months of the follow-up time. The KM survival curves switched as men had a 
better survival probability until about 62 months of the study. To demonstrate, the one-year, 2-
year, 3-year and 4-year survival rates for women were estimated as 0.81, 0.70, 0.59 and 0.41, 
respectively, while the rates for men were 0.79, 0.63, 0.51 and 0.41. Eventually again the trend 
switched as the 5-year survival rate was 0.29 for women and 0.36 for men. 
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Figure 7. KM survival curve for chronic dialysis patients by gender  
 
 
The quantified difference obtained from the log-rank statistical test suggests that there 
was no difference in the survival experience of men and women (p=0.263). Thus, the two 
survival curves (male and female) are not statistically different during the study period 
(Appendix G). Table 5 displays the log-rank test results for the male and female dialysis patients.   
 
Table 5. Log-rank test for gender 
   Number of patients Number of deaths 5-year survival rate 
Gender      
    male 453 184 0.36 
    female 270 100 0.29 
                               Log-rank test:  p= 0.263  
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5.5.3. KM curves for modality 
Figure 8 displays the KM survival curves by baseline modality of the whole cohort. The 
median survival time for HD and PD patients was 38.7 and 39.8 months, respectively. As 
illustrated, there is a higher survival probability for PD patients early in follow-up. For example, 
one-year survival rate for PD patients equals 0.88 while this value is 0.78 for HD patients. Up to 
18 months, the survival probability for PD is higher than that for HD, but thereafter the two 
survival curves are at about the same level. This graph indicates that up to 18 months the PD 
modality has better survival outcome than the HD but has about the same effect thereafter. To 
demonstrate, 2-year, 3-year, 4-year and 5-year survival for PD patients estimated as 0.65, 0.54, 
0.42 and 0.28, while this rates were estimated as 0.65, 0.54, 0.41 and 0.34 for HD patients, 
respectively.  
 
Figure 8. KM survival curve for chronic dialysis patients by type of modality  
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The log-rank test for equality of survivor functions had a p-value of 0.464, confirming 
that the survival experience among two modalities was not significantly different (Appendix H). 
In fact, during the study follow-up time, type of dialysis modality (HD vs. PD) did not 
statistically differ despite the survival advantage of PD over HD during the early follow-up time 
(Table 6).  
Table 6. Log-rank test for baseline modality 
		  Number of patients Number of deaths 5-year survival rate 
Modality      
    HD 592 238 0.27 
    PD 131 46 0.28 
                                   Log-rank test, p= 0.464  
 
5.6. Multivariate analysis 
The multivariate Cox proportional hazard model was calculated using a backward 
elimination variable selection procedure. Thus, in the first step the model was estimated with all 
the variables and the survival outcome. In succeeding iteration, non-significant variables (i.e., 
those that added least to the model) were eliminated in a stepwise order to achieve model 
parsimony. P-value > 0.2 and p-value > 0.1 were considered as the two exclusion criteria in the 
elimination procedure, resulting in models A and B, respectively. During the multivariate 
analysis, the age variable was considered as a confounder. The goal was to describe the effects of 
comorbidities, type of modality and gender on survival outcome adjusted for age. 
During the backward elimination procedure, certain variables were retained and others 
dropped. In model A, variable elimination proceeded until all remaining variables in the model 
had p-values less than 0.2, resulting in a four variable model (Table 8 and Appendix I). As 
already described, at each subsequent step, the variable that added least to the model was 
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eliminated. In the first step, the initial model contained all thirteen variables: age, gender, 
modality, cardiac disease, HTN, CVA, MI, cancer, diabetes, lung disease, dementia, depression 
and bipolar disorder. In this step, depression was eliminated from the initial model, as it had the 
highest p-value, equal to 0.789. In the second step, CVA, with its p-value of 0.675, was 
eliminated. In step 3, caner showed the smallest contribution to the model, with a p-value of 
0.669, so it was dropped. Subsequently, from steps four to five cardiac disease was dropped with 
the p-value of 0.519. Continuing the elimination procedure led to model A, where all variables 
(i.e., age, HTN, bipolar, lung disease) had p-values of less than 0.2 (Table 8).  
The backward elimination continued with the cut-off of 0.1. In the two subsequent steps, 
bipolar and lung disease were eliminated with the p-values of 0.184 and 0.173, respectively. As a 
result, the final reduced model B contained only two variables: age and HTN. As illustrated in 
Table 7 and Appendix I, the backward elimination procedure with the cut-off of 0.1 took twelve 
steps in this study (counting Step 1 as the full model with all variables included, and Step 12 as 
the eventual reduced model). After step 12, no variable had a p-value above 0.1 (Table 7).  
The majority of variables were not statistically significant enough to retain in either final 
model; thus, depression, CVA, cancer, cardiac disease, modality, diabetes, dementia, gender and 
MI were excluded. Type of modality was dropped from the backward procedure in the step 5 
with the p-value of 0.433, indicating the non-significant impact of modality on survival (Table 7 
and Appendix I).  
Table 8, indicates the final two models with corresponding adjusted HR and p-values. Of 
the four retained variables in model A, bipolar and lung disease were insignificant predictors of 
survival, at the 0.05 significance threshold. Both bipolar and lung disease were positively 
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associated with mortality in this population without a statistical significance impact (bipolar: 
adjusted HR= 1.74, p= 0.184, lung disease: adjusted HR=1.21, p=0.154), (Table 8).  
Both HTN and age remained significant throughout all steps of the backward elimination, 
and the estimated effects persisted (Appendix I and Table 7). In both final models A and B, 
hypertensive dialysis patients had a lower risk of mortality than the non-hypertensive group 
(model A: adjusted HR=0.62, p= 0.013, model B: adjusted HR=0.65, p= 0.023). Older patients 
had a higher risk of mortality in both model A and model B (model A: adjusted HR=1.05, 
p<0.001, model B: adjusted HR= 1.05, p<0.001). 
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Table 7. Backward elimination variable selection steps with the cutoff of 0.01 
step Included variables Eliminated variable 
Adjusted 
HR 95% CI P-value 
1 age, gender, modality, cardiac disease, HTN, CVA, MI, cancer, diabetes, lung disease, dementia, depression, bipolar Depression 1.04 0.79-1.36 0.789 
2 age, gender, modality, cardiac disease,  HTN, CVA, MI, cancer, diabetes, lung disease, dementia, bipolar CVA 0.94 0.72-1.24 0.675 
3 age, gender, modality, cardiac disease, HTN, MI, cancer, diabetes, lung disease, dementia, bipolar Cancer 0.95 0.74-1.22 0.669 
4 age, gender, modality, cardiac disease, HTN, MI, diabetes, lung disease, dementia, bipolar 
Cardiac 
disease 0.91 0.68- 1.21 0.519 
5 age, gender, modality, HTN, MI, diabetes, lung disease, dementia, bipolar Modality 0.88 0.64-1.21 0.433 
6 age, gender, HTN, MI, diabetes, lung disease, dementia, bipolar Diabetes 1.11 0.85-1.44 0.451 
7 age, gender, HTN, MI, lung disease, dementia, bipolar Dementia 0.80 0.51-1.27 0.343 
8 age, gender, HTN, MI, lung disease,  bipolar Gender 0.87 0.68-1.11 0.258 
9 age, HTN, MI, lung disease, bipolar MI 0.87 0.67-1.12 0.278 
10 age,  HTN,  lung disease, bipolar Bipolar 1.74 0.77-3.94 0.184 
11 age,  HTN, lung disease Lung disease 1.20 0.92-1.56 0.173 
12 age, HTN - - - - 
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Table 8. Adjusted risk of mortality in two final models 
                     Model A             Model B 
Variable Adjusted HR P-value             Adjusted HR P-value 
Age 1.05 <0.001         1.05 <0.001 
HTN 0.62 0.013          0.65 0.023 
Bipolar 1.74 0.184        - - 
Lung disease 1.21 0.154        - - 
 
5.7. Verification of Cox proportionality assumption 
     The proportional assumption was tested both globally and individually on each of the retained 
variables in the final models. In both models, the proportionality assumption was satisfied as 
both the global p-value and the individual p-value for each variable were greater than 0.05. 
Therefore, the statistical inferences and prediction based upon the obtained models were reliable. 
Table 9 illustrates the results of proportionality assumption testing for models A and B.  
 
Table 9. Proportionality assumption testing 
 Model A Model B 
Variables P-value P-value 
Age 0.266 0.194 
HTN 0.812 0.621 
Bipolar 0.782 - 
Lung disease 0.142 - 
Global 0.393 0.381 
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5.8. Model selection  
    Likelihood Ratio Test (LRT) is a statistical test used for the Goodness of Fit (GOF) 
comparison of two nested models. In the context of survival analysis, every Cox proportional 
hazard model can be compared with a null model (i.e., a model with no predictors, HR=1, b=0) 
to examine whether the obtained model fits the data or not. The LRT is based on the comparison 
of likelihoods of the two models which can be written as follows: 
! = 2 ln &'&( = 2 ln &' − ln &( 9  
The D mathematically equals two times the difference in the logarithms of the likelihoods of two 
models.  In this formula, LA denotes the partial likelihood of the full model, and LB equals the 
partial likelihood of the nested model. Given the null hypothesis that the two models fit the data 
equally well, the LRT statistics has an approximate chi-square distribution with the pA-pB degrees 
of freedom, where pA and pB denote the number of parameters in models A and B.  
     As mentioned, the backward selection procedure came up with model A (a full model with 
four covariates) and model B (a model nested within model A and having two covariates).  LRT 
was used to test the null hypothesis if the null model is a preferred model in terms of providing 
satisfactory fit to the data or not. The p-values (less than 0.05) obtained from LRT revealed that 
both full and nested models fitted better than the null model with no predictors (Table 10).  
Table 10. Model comparison 
 D P-value 
Model A 110 <0.001 
Model B 106.7 <0.001 
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The difference between the log likelihood statistics of the nested model and the log 
likelihood statistics of the full model was computed as: 2(1599.9-1598.3) = 3.2. The test 
statistics has a chi-square distribution with degrees of freedom equal to the difference in the 
number of covariates between the two models: 4-2 = 2, where 4 and 2 represent the number of 
covariates in model A and model B, respectively. Thus χ2 with 2 degrees of freedom was 
compared with D. Since D = 3.2 is less than +,, = 5.99, null hypothesis (i.e., H0: model A = model 
B) is not rejected, and both models are statistically equivalent. In other words, models A and B 
provided adequate fit. 
According to the principle of parsimony as the qualitative component of the model 
selection, it is worthwhile adopting model B because it is simpler than model A. Since both 
models provided adequate and similar fit, model B, as a more parsimonious model, was 
preferred.  
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 Chapter 6: Discussion 
6.1. Summary 
      The dialysis population represent one of the fastest-growing epidemics globally and in 
Canada, with a higher mortality rate than general population. In addition, this high rate of 
mortality, life expectancy among dialysis patients still remains significantly reduced due to the 
high prevalence of comorbid conditions such as Cardio Vascular Disease (CVD) and diabetes. 
As the epidemic of dialysis patients continues to emerge in Ontario, it is imperative to estimate 
the survival rate trends of dialysis centers and explore the survival outcome with different 
modalities. Patient survival has been considered an important index of overall adequacy of 
treatment in the majority of chronic illnesses such as cancer, and dialysis population (Charra et 
al., 1992). Accurate and comparable analysis of survival data is highly needed in different renal 
centers as some of the dialysis technologies may be having adverse outcomes while showing 
early promising results in some other centers.  
In recent Canadian literature, only a few studies have compared the survival outcome of PD 
and HD patients (Yeates et al., 2012). Moreover, the exclusion of acute dialysis patients and 
inclusion of chronic dialysis patients have influenced the nature of the analytic sample. Previous 
studies lacked clear definition of chronic and acute dialysis, and some studies even failed to 
mention the exact description of the included patients in terms of chronic and acute. Multiple 
systems in GRH and existing sections were reviewed and screened by three individuals with 
clinical expertise and knowledge. Using KM survival curves in this study provided simple and 
quick insights at the survival experience of the cohort, and the Cox proportional hazard 
regression model yielded the association between variables and the survival outcome.  
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The primary objectives of this study were to estimate the survival rate of incident chronic 
dialysis patients in GRH, compare the survival experience of patients receiving PD and HD, and 
finally identify significant predictors of mortality. In this regional community hospital, this 
research is the first attempt to estimate the survival rate of dialysis patients and investigate the 
survival outcome of HD and PD. There are three main points from this study which will be 
discussed separately:  1) Survival rate obtained from the analysis of patients treated with dialysis 
in GRH was comparable with other reported statistics, 2) During the study period, PD and HD 
had a similar survival outcome 3) Age and hypertension (HTN) had a significant impact on 
survival outcome. The results of this study may be used in counseling of patients requiring renal 
replacement therapy in GRH providing insight about their survival experience.  
 
6.2. Interpretation of key findings  
6.2.1. Survival rate of dialysis patients in GRH 
This study analyzed survival among 723 incident chronic dialysis patients in GRH during the 
study period of January 1th, 2012 to September 30th, 2017. The overall patients’ survival rate 
obtained from this study, for the one-year, 2-year, 3-year, 4-year and 5-year were 0.80, 0.65, 
0.54, 0.41 and 0.34, respectively. These survival rates in GRH were compared with recent 
statistics in Canada and USA such as CORR (Canadian Organ Replacement Registry)1 and 
USRDS (United States Renal Data Systems)2 national renal registries. The survival rates in this 
cohort were consistent with CORR and USRDS, illustrating high standards of provided care in 
                                                
1 Canadian Organ Replacement Register (CORR) at the Canadian Institute for Health Information (CIHI), 2016, 
retrieved at: https://www.cihi.ca/en/canadian-organ-replacement-register-2016 
2 United States Renal Data Systems (USRDS), 2017, retrieved at: https://www.usrds.org/reference.aspx 
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the current renal program in GRH. In particular, 90-day survival of dialysis patients in GRH 
(0.94) were higher than survival of incident dialysis patients reported in CORR and USRDS 
reports with 0.91 and 0.92, respectively. One-year survival rate in GRH (0.80) was similar to the 
CORR and USRDS reports with the rate of 0.82 and 0.80, respectively. Survival outcome of 
dialysis patients in GRH compared to other registries highlights the clinical efficacy of the 
current renal program in this center. 
6.2.2. Comparison of survival outcomes by modality 
      In an analysis of a contemporary cohort of 592 (81.8%) HD and 131 (18.1%) PD, patients in 
both modalities had a similar averaged age at the baseline (HD: 64.93, PD: 64.52, p=0.784). The 
prevalence of diabetes was significantly higher in PD patients than in HD patients (HD: 62%, 
PD:72%, p=0.045). On the other hand, cancer and lung disease were statistically more prevalent 
in the HD group (cancer: HD:33%, PD:22%, p=0.014, lung disease: HD:25%, PD:16%, 
p=0.028). Although in the preliminary analysis, unadjusted KM estimates showed a superior 
survival rate for PD compared to HD patients during the first 18 months after dialysis initiation, 
the overall survival outcomes of HD and PD patients were similar (log-rank test, p=0.464). 
Short-term survival rates of PD and HD patients during the first 18 months of dialysis initiation 
were 88% vs. 77% at three months, 88% vs. 77% at one year and 77% vs. 70% at 18 months, 
respectively. After 18 months of dialysis initiation, both PD and HD groups had similar survival 
rates (i.e., 65% at two years, 54% at three years and 28% at 68 months (endpoint of the study), 
respectively). The initial survival advantage of PD over HD may be explained by HD patients 
often having poor prognoses than PD patients. In fact, most severely ill patients requiring urgent 
treatment start renal replacement therapy with HD (Kim et al., 2014; Choi et al., 2013; Marshal 
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et al., 2015). Some other studies attribute this advantage to the younger distribution of PD 
patients (Wang et al, 2013); while this difference was not evident in this study. In our 
multivariate Cox proportional hazard model, type of modality was eliminated in the backward 
elimination procedure, adjusting for other variables with the p-value of 0.43 and hazard ratio of 
0.88, illustrating the insignificance impact of modality on survival outcome during the study 
period.  
     The findings of the current study are in keeping with those of several studies, particularly 
Canadian ones, investigating the effects of type of modality on the survival of dialysis patients 
(Wong et al., 2017; Yeates et al., 2012; Fenton et al., 1997). A very recent retrospective cohort 
study by Wong et al., in 2017, analyzing 874 dialysis patients in seven regional dialysis centers 
in Ontario, yielded an insignificant effect of modality on survival and similar association of HD 
and PD with mortality during a nine-year study period (HR=1.09, 95% CI:0.82-1.45). Likewise, 
a number of large registry-based studies showed similar survival outcomes for both modalities 
(Yeates et al., 2012; Huang et al., 2008; Wang et al., 2013). The largest Canadian study, 
conducted by Yeates et al., in 2012, analyzing CORR data, revealed similar outcomes for both 
modalities during 13 years of follow-up. Based on Intention to Treat (ITT) analysis (i.e., 
attributing the hazard to the initial exposure regardless of any changes during the exposure 
(Marshal et al., 2015)) using the Cox proportional hazard model, the survival outcome remained 
the same for both HD and PD, with the average HR of 0.99 for the most-recent cohort (2001-
2004) (Yeates et al., 2012). Similar to the KM survival rates obtained from GRH dialysis cohort 
by type of modality, CORR data showed an early survival advantage of PD over HD (one-year 
survival rate, HD:0.85, PD:0.9). Another similarly conducted study in Canada reported that the 
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use of CAPD/CCPD or HD is not associated with an increased risk of mortality (Fenton et al., 
1997).  
    Survival analysis based on large-scale registries from other countries such as Taiwan have 
illustrated similar results. Again, using Cox proportional hazard and ITT analysis, Huang et. al., 
(2008) revealed that PD and HD patients experienced similar short-term and long-term survival 
outcome, after adjusting for demographic and clinical variables. In accordance with the current 
study’s findings, PD and HD patients had similar long-term survival outcomes (Appendix D). No 
statistical difference was observed between these two groups (log-rank test, p=0.125). In total, 
the survival rates obtained from the Taiwan registry were higher than those estimated for GRH, 
except the one-year survival rates for PD patients which were similar (Taiwan:89%, GRH:88%). 
Another study in Taiwan, analyzing a subgroup from the same registry data, yielded similar 
overall survival among non-diabetic dialysis patients with a history of stroke (HR=1.2, 95% 
CI:0.96-1.5) (Wang et al., 2015).  
     In addition to large cohort studies, two small cohort studies with different study designs 
(retrospective vs. prospective) and inclusion strategies for patients (incident vs. prevalent) found 
similar survival outcome for the two dialysis techniques. Retrospective ITT analysis of incident 
dialysis patients in Hatzikosta General Hospital (HGH) in Greece by Andrikos et al. in 2008 
exhibited no significant difference between HD and PD patients (55% vs. 50%; log-rank test, 
p=0.5), whereas the As-Treat analysis (AT, i.e., attributing the hazard to the last exposure 
(Marshal et al., 2015)) in this single center study illustrated significantly higher survival for PD 
patients HD ones (79% vs. 60%; log-rank test, p=0.04) (Andrikos et al., 2008). In comparison 
with the survival rate obtained in GRH, KM estimates for ITT approach revealed higher survival 
rates for patients in HGH center in Greece. The higher average age in incident dialyses patients 
  
75 
at GRH (65 years old in GRH vs. 53 years old in HGH) may explain this difference. Analyzing 
the survival rates of prevalent dialysis patients recruited from three different dialysis centers in 
south-west Poland in four-year prospective study period showed that type of modality did not 
exert a significant impact on patient survival (log-rank test, p=0.83) (Madziarska et al., 2013).  
      As discussed, the majority of Canadian studies have highlighted the similarity of survival 
outcome among HD and PD patients (Yeates et al., 2012; Wong et al., 2017; Fenton et al., 1997); 
however, according to Sood et al., (2012) this finding might not be generalizable to all ethnic 
groups in Canada. Large-scale survival analysis of aboriginal patients, showed that PD modality 
was associated with higher risk of mortality (HR=1.36, p=0.001). According to studies in Taiwan 
(2013) and France (2011), patients with particular comorbid conditions had a poorer survival on 
PD compared to HD. Wang et al, in 2013, found that Taiwanese dialysis patients with pre-
existing diseases, including diabetes or CVD, had inferior survival with PD compared to those 
receiving HD (HR=1.34, p<0.001). Similarly, Sens et al., in 2011 showed that incident dialysis 
patients with Congestive Heart Failure (CHF) commencing dialysis with PD in France 
experienced poorer survival rate than those with HD (HR=1.48, p<0.0001). The inclusion of 
specific ethnic groups of dialysis patients as well as those with specific type of comorbidities 
may explain this difference, with other studies indicating similar outcome for both modalities.  
       A few other investigators have reported superior outcomes for PD over HD, particularly in 
younger group of patients (Marshal et al., 2015; Choi et al., 2013). A nationwide prospective 
Korean study in 2013 by Choi et al., exhibited significantly improved survival outcomes for PD 
patients (HR=0.63, 95% CI: 0.36-1.08). Comparison survival analysis of Australian and New 
Zealand dialysis populations in a time-dependent approach also noted this observation, as the 
survival of PD patients was greater than that of HD patients during the study follow-up (Marshal 
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et al., 2015). Generally, authors tend to speculate that the superiority of PD over HD might be 
due to the possible improved patient selection for PD and the lesser burden of comorbidities in 
this group over time (Choi et al., 2013; Marshal et al., 2015).  
      Retrospective study design, inclusion of incident dialysis patients with a specific time-lag, 
similar geographic location (except in the study by Andrikos et al., in 2008 conducted in 
Greece), and an ITT analysis approach were the characteristics in common among the current 
study and the studies by Wong et al., (2017), Yeates et al., (2012) and Andrikos et al., (2008). 
The last two studies applied both ITT and AT analysis approaches to investigate any possible 
statistical differences in the modality comparison. It is worthwhile to mention that the results 
from ITT analysis in both studies were similar to our study’s findings. Despite the use of ITT 
analysis in two other studies by Sood et al., (2012) in Canada, and Choi et al., in Korea, (2013), 
the survival outcomes of HD and PD were diverged. A possible explanation for this variation 
may be the large sample size and inclusion of aboriginal patients in the study by Sood et al., 
(2012) and the prospective study design, small cohort size and different geographic location (i.e., 
Korea) in the study by Choi et al., (2013). Similar findings from Canadian studies, including 
ours, highlight the equivalency of both modalities in terms of survival outcome and therefore can 
be offered equivalently to incident dialysis patients.  
6.2.3. Significant predictors of survival outcome 
From the current analysis, we were able to identify significant variables associated with 
survival outcome in GRH chronic dialysis patient population. During all the steps of backward 
elimination procedure adjusting for age, HTN remained significant with the exclusion cut-offs of 
greater than 0.1 and 0.2 p-values. Multivariate Cox proportional hazard regression has 
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highlighted the reverse association of HTN and survival outcome in this cohort. The results 
suggest that the presence of HTN as a coexisting comorbidity at the time of dialysis initiation 
was strongly associated with improved survival outcome (Model A: HR=0.62, p= 0.013, Model 
B: HR=0 0.65, p= 0.023). According to model A, non-hypertensive dialysis patients at the 
baseline had a higher risk of death compared to hypertensive dialysis patients, with the adjusted 
HR of 0.65.  
       The majority of the included chronic dialysis patients were hypertensive at the time of 
dialysis initiation (88.8% of the whole cohort). The distribution of hypertensive patients was 
similar for both types of modalities (HD: 88%, PD: 92%, p=0.201). Consequently, this finding 
may be generalizable to both groups of dialysis patients. Supplementary analyses to determine 
whether there was a statistical difference in the group of hypertensive and non-hypertensive 
patients did not reveal any significant differences in the groups of hypertensive and non-
hypertensive patients in terms of age (Table 2).  
  The finding of this study regarding HTN was supported by several epidemiological 
studies confirming the U-shaped relationship between mortality and HTN. Some of the existing 
studies refer to this phenomenon as “reverse epidemiology”, indicating a paradoxical association 
between mortality and the effect of hypertension in dialysis patients. Kalantar-zadeh et al., 
(2005) reported the survival advantages of high blood pressure among dialysis patients. 
Similarly, survival analysis of HD patients enrolled in the DOPPS registry demonstrated that a 
history of hypertension was significantly associated with decreased risk of mortality in both 
univariate (HR=0.85, p<0.0001) and multivariate analysis (HR=0.74, p<0.0001) (Goodkin et al., 
2003). The findings of the DOPPS study coincided with the association obtained in this study, 
and with Hwang et al.,’s investigation of various comorbidities’ impacts on the survival outcome 
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of HD patients in Taiwan, which also illustrated a reverse association of hypertension presence at 
the time of commencing dialysis (HR=0.79, CI:0.7-0.89) (Hwang et al., 2010). Furthermore, in a 
similar study conducted in Taiwan in a duration of 10 year follow-up, HTN was a statistically 
significant protective variable for mortality (HR=0.84, p<0.001) (Wang et al., 2013). Comparing 
survival experience of HD and PD patients with and without history of CVD in this study, 
highlighted the history of HTN as an independently protective effect on survival outcome (Wang 
et al., 2013).  
     As mentioned, the linear relationship between HTN and increasing cardiovascular, 
cerebrovascular events and mortality in the general population is indisputable (Lim et al., 2012; 
Perkovic et al., 2007). In the same way, in the dialysis population, some studies have showed the 
increased risk of mortality in the presence the of HTN. In contrast to the reverse epidemiology of 
hypertension, survival analysis of Indonesian hemodialysis patients by Purnama et al. (2015), 
suggested increased risk of mortality in hypertensive patients with the hazard ratio of 1.04. In 
line with these reports that contradict our findings, Lucas et al. (2003), found uncontrolled HTN 
to be an independent risk factor for both all-cause mortality (HR=1.79, p=0.01) and 
cardiovascular mortality (HR=2.93, p=0.00). Uncontrolled HTN was defined as blood pressure 
greater than 140/90 mm Hg, whereas this threshold was above 150/85 mm Hg in the study by 
Agarwal et al., (2003). Two cohort studies in Tassin, France, reported the independent 
association of HTN and increased risk of mortality in HD patients (Charra et al., 1992). 
According to the literature, however, some studies have failed to show any significant 
association between existence of HTN as a comorbid condition and survival in dialysis patients 
(Andrikos et al., 2008; Yang et al., 2015; Huang et al., 2008; Wang et al., 2016). 
  
79 
     As discussed, the current finding of this study indicated that the presence of hypertension as a 
comorbid condition at the time of initiating dialysis showed a protective effect on survival 
outcome. There are several possible explanations for this finding in the literature, for instance, 
discrete (binary) categorization of hypertension at the baseline as (yes or no) instead of using 
blood pressure as a continuous variable (SBP, DBP) (Agarwal, 2005; Hwang et al., 2012). 
Binary categorization of hypertension indeed did not reveal how severe it was at the baseline. 
This categorization, due to insufficient information on blood pressure measurements, and 
duration of antihypertensive medication use or any relevant treatment at the baseline, could have 
resulted in reporting normotensive or well controlled hypertension patients as hypertensive. To 
demonstrate, there is a possibility that some patients who were being treated with 
antihypertensive medication therapy for a long time and who had already become normotensive 
were categorized as hypertensive (Hwang et al., 2012). Based on the review conducted by 
Agarwal in 2005, the use of antihypertensive medication treatment is associated with improved 
survival regardless of how well the high blood pressure is under control. Emerging evidence on 
impact of antihypertensive medications on dialysis patients’ survival also provides independent 
cardio protection in hypertensive patients. For example, use of ACE1 and ARB2’s 
antihypertensive medications help decreasing glomerular pressure and protect the nephron. 
A number of large cohort studies confirmed elevated risk of mortality for dialysis 
hypotensive patients and did not report a higher risk of mortality for those with increased level of 
blood pressure, which suggests the U-shaped relationship (morality and hypertension) (Agarwal, 
2005). Clinically, hypotension is an indicator for significant comorbidities such as heart failure 
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or ischemic cardiomyopathy (Molnar et al., 2012). Several studies confirmed that hypotension 
had a stronger signal for mortality that HTN in dialysis patients. Kalantar-zadeh et al., (2005), 
illustrated that a range of normal to low blood pressure is associated with poor clinical outcome 
among dialysis patients. Likewise, both time varying and discrete categorization of hypertension 
in a study by Li z et al., (2006) showed that risk of mortality tends to be greater at normal and 
low levels of blood pressure. In the current study, there is a possibility that hypotensive patients 
were reported and categorized as non-hypertensive, reflecting poor survival outcome.  
     The other possible explanation is uncertainty about the definition of HTN presence at dialysis 
initiation. It was also not clear what specific threshold was considered for presence of HTN. 
Some of the studies defined HTN as taking current antihypertensive medication or self-report of 
having a previous clinical diagnosis (DOPPS) while others identified a specific threshold for 
normal blood pressure (Tong et al., 2016). Tong J et al., defined HTN as if the patient was taking 
antihypertensive medication or had a blood pressure of greater than 140/90 mm Hg in two 
different occasions while the study by Lacus identified uncontrolled hypertension with a blood 
pressure greater than 140/90 mm Hg. In another study by Agarwal et al., HTN was defined as an 
average pre-dialysis blood pressure greater than 150/85 mm Hg (Agarwal et al., 2003). In spite 
of widely used of these thresholds in this context, some reports show routine pre-dialytic blood 
pressure recordings are not sufficient to accurately diagnose HTN. High variability in session-to-
session blood pressure may explain the poor diagnostic accuracy of pre-dialysis blood pressure 
recordings (Georgianos & Agarwal, 2016).  
Finally, there is possibility that non-hypertensive patients had other preexisting diseases 
or clinical abnormalities that were not captured in this study. In this case, there is a possibility 
that presence of HTN as a risk factor was confounded by unmeasured parameters contributed to 
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the poor survival outcome. Adjustments for laboratory values and other comorbidities in other 
studies may explain the differences in findings between this study and others.  
6.2.4. Non-significant predictors 
    The presence of comorbidities (i.e., other than HTN) and mental health disorders did not have 
a significant impact on the survival outcome in the current study. All the comorbidities except 
two of them which were lung disease and HTN and all mental health disorders except bipolar 
were dropped during the backward elimination procedure. In the model A with the exclusion cut-
off of p-value>0.2, HTN and age were the only significant variables while lung disease and 
bipolar were two non-significant variables. In model B with the exclusion cut-off of p-
value>0.01, HTN and age remained as the only significant variables without non-significant 
variables in the model. Other than comorbidities and mental health disorders, gender also did not 
confer a significant effect on survival outcome which is highly supported by several studies 
(Yang et al., 2015; Kim et al., 2014; Serafinceanu et al., 2014; Choi et al., 2013; Sens et al., 
2011; Yeates et al., 2012; Shabankhani et al., 2016; Sood et al., 2012). For example, a survival 
analysis of 500 HD patients in Mazandaran, Iran using three hospitals data during a 6-year study 
period demonstrated non-significant effect of gender on mortality (Shabankhani et al., 2016). 
Published results from two large cohort studies in Canada by Yeates et al., (2012) and Sood et 
al., (2012) revealed that gender did not influence survival. Another large-scale study in France 
by Sens et al., (2011) also confirmed the non-significant of this association. In accordance with 
these findings, two prospective studies compiling data from different hospitals in Korea and 
Poland, respectively with small cohort size also highlighted this association (Choi et al., 2013; 
Madziarsk et al., 2013). It is worthwhile to mention that direction of the association (i.e., 
  
82 
improved survival for females) in the majority of these studies were similar to the current study 
(Shabankhani et al., 2016; Choi et al., 2013; Madziarsk et al., 2013).  
Cancer: In this study history of cancer at the baseline did not appear to affect the 
outcome significantly as it was also found in other studies. A nationwide prospective cohort 
study in Korea founded no significant effect of cancer on the survival outcome (Choi et al., 
2013). A retrospective study by Béchade et al. (2017), also did not reveal any association 
between history of cancer at the baseline and survival outcome among incident dialysis 
population. Similarly, survival analysis of aboriginal and Caucasian Canadian dialysis patients 
receiving HD and PD therapies, identified history of cancer as a non-significant predictor of 
mortality (Sood et al., 2012). Another study in Taiwan, demonstrated the non-significant impact 
of cancer as a comorbid condition at the baseline on survival of PD and HD patients with prior 
stroke (Wang et al., 2016). Higher prevalence of cancer in HD group of patient was consistent 
with many studies in this context such as those conducted by Sood et al., (2012) Wang et al., 
(2013, 2016) and Choi et al., (2012).  
Diabetes: Presence of diabetes at the dialysis initiation adjusted for age, also did not 
confer a significant influence on survival outcome. Multiple studies have found non-significant 
impact of diabetes on survival. In a retrospective study by Koch et al., (2006) analyzing survival 
data in a single-center in Germany, diabetes proved not to be an independent predictor of 
mortality. Another prospective registry-based, observational study in Scotland revealed that 
presence of diabetes did not influence the 2-year survival of patients initiating dialysis (Metcalfe 
et al., 2003). A French study analyzing survival experience of PD and HD patients with CHF 
also demonstrated non-significant impact of history of both types of diabetes (i.e., type 1 and 
type 2) on survival outcome (Sens et al., 2011).  
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Lung disease: Although lung disease remained in the model A during the backward 
elimination, similar to other comorbidities did not affect survival outcome. Consistent with other 
studies’ findings, a very recent multicenter prospective cohort study in Korea by Park et al., 
(2018) demonstrated non-significant impact of chronic lung disease history on survival using 
Cox proportional hazard model. Direction of the obtained association in this study was similar to 
our study as well. Similar to the study by Park et al., (2018) mortality comparison between HD 
and PD patients in France revealed that chronic lung disease did not exert significant effect (Sens 
et al., 2011).  
Cardiac disease, MI and CVA: On the age-adjusted multivariate analysis, along with 
other comorbidities except HTN, presence of MI, cardiac disease and CVA did not exert a 
significant impact on survival which is also supported by some of the studies such as a study by 
Xia et al., (2017). In this observational study incident adult PD patients were enrolled to build a 
predictive model using Lasso Cox regression model. Presence of MI was not a significant 
predictor for mortality in this population (Xia et al., 2017). In multiple studies CAD as the most 
common type of cardiac disease showed nonsignificant effect of the survival outcome. In an 
observational study survival analysis of Australia and New Zealand and Transplant Registry 
(ANZDATA) data, identified CAD as a non-significant predictor of all-cause mortality during a 
5-year study period (Lawton et al., 2015). Similarly, a retrospective small cohort study in 
Greece, found CAD as an insignificant variable in a survival comparison of incident HD and PD 
patients (Andrikos et al., 2008). Despite the consistency of these findings, some of the studies 
pointed out CAD and MI as important mortality risk factors in dialysis populations (Wang et al., 
2013; Tong et al., 2016; Lee et al., 2014 & Hocher et al., 2008).  
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Another statistically insignificant relationship in the current study was the impact of CVA 
on survival. In spite of CVA prevalence among chronic dialysis patients, there are a number of 
studies in the literature supporting this finding. In an observational prospective study 
investigating the potential associations of several risk factors with early and overall mortality in a 
single-center dialysis cohort in the UK, presence of CVA was not significantly associated with 
mortality (Cherukuri & Bhandari, 2009). There are some possible explanations for the existing 
difference in this context such as merging different heart failure problems and risk factors into 
one category in other studies (e.g., combining MI, CAD and CVA into one category), variability 
in study designs, statistical techniques, follow-up duration, sample size, demographic 
characteristics, etc.   
Mental health disorders: Many authors have discussed the importance of assessing 
psychiatric disorders among candidates for initiating dialysis; however, investigations of the 
associations between these groups of comorbidities and survival outcome among incident 
dialysis population revealed different results (Rakowsk et al., 2006; Rosenthal et al., 2012). 
Similar to our findings, early studies using valid measures of depression provided preliminary 
evidence that all-cause mortality was not significantly affected by the presence of depression. 
For instance, survival analysis of 97 patients undergoing renal replacement therapy such as HHD 
and PD, indicated presence of depressive symptoms did not influence the survival outcome 
(Devins et al., 1990). A prospective, longitudinal, multicenter study of urban HD patients, also 
demonstrated that depression was not a mortality predictor (Kimmel et al., 1998).  
Subsequent studies also did not find any association between baseline depression 
symptoms and increased risk of mortality among incident dialysis patients (Kimmel et al., 2000; 
Boulware et al., 2006). Extensive evaluation of depression symptoms among 323 chronic HD 
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patients revealed that impact of depression on survival outcome was attenuated when adjusted 
for comorbidities, suggesting presence of a complex relationship between depression and clinical 
characteristics (Fan et al., 2014). There are some studies revealing significant impact of mental 
health disorders such as a study by Goodkin et al., (2003), examining all psychiatric disorders at 
the same time similar to our study. Survival analysis of HD patients across different regions in 
DOPPS registry as a prospective, observational cohort also demonstrated significant impact of 
mental health disorders such as dementia, depression and bipolar on survival (Goodkin et al., 
2003). In DOPPS registry, history of dementia along with history of Parkinson disease was 
categorized as neurologic disease comorbidity condition. Both depression and bipolar along with 
a history of alcohol and schizophrenia were categorized as psychiatric disorders.  
Different study designs, large registries vs. single center, various criteria for evaluating 
mental health disorders, different categorization and combining various disorders into one 
category may explain different results. Moreover, there is a scarcity of studies assessing the 
impact of mental health disorders, particularly dementia and bipolar. The low prevalence of 
mental health disorders variables in this study suggests that mental health status might be 
underreported in the GRH renal systems. It is therefore likely that patients who were identified as 
not having mental disorders would not have been assessed or even asked for such problems. 
Such possible underreporting or misclassification generally would bias obtained associations 
toward lack of statistical significance (Gordis, 2013).  
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6.3. Strengths, limitations and future direction 
6.3.1. Strengths 
Local hospital-based renal data analysis conducted in this research is an important and 
timely contribution to existing dialysis outcomes in Canada. This survival analysis using GRH 
renal data is a first attempt estimating survival rates among chronic dialysis patients in the 
Waterloo region. The results from this study can help to provide relevant guidance for the 
individualization strategies for chronic dialysis patients receiving care at GRH. Although there 
have been a number of studies in various geographic locations on survival outcome, they have 
largely neglected various important comorbidities. No contemporary studies on the survival 
analysis of incident chronic dialysis patients in Canada have included a wide range of 
comorbidities and mental health disorders in their models in the current era. However, obtaining 
survival outcomes and the relevant impact of comorbidities, can provide some relevant insights 
to nephrologists and clinical teams. Using these insights on similar survival outcome of HD and 
PD modalities will help enhance long-term and short-term prognoses, particularly for patients in 
GRH or for those who are similar to this cohort in terms of both ethnic and medico-social 
aspects.  
Information from this analysis will contribute to building and developing patient profiles, 
resulting in better outcome prediction for new dialysis patients. Model validation has 
demonstrated significant prognostic information gained by applying the two models. The Cox 
proportional hazard model may eventually evolve into ‘counseling-decision tool’ to facilitate 
decision making regarding modality choices at dialysis initiation.  
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Previous studies have not always accounted for incident versus prevalent and acute versus 
chronic. The 30-day lag in differentiate between chronic and acute dialysis patients was 
considered for evaluating survival in this cohort. Survival rates obtained from this study clearly 
indicate the current status of dialysis therapy among incident chronic patients receiving dialysis 
in GRH. Owing to the robust data collection and relatively long follow-up (up to 68 months) 
period of this study, the results can be compared with other regional or population-based cohorts 
and single center studies in Canada. 
6.3.2. Limitations  
As with other retrospective observational studies, this study also has limitations inherent 
to such a study design.  In view of the retrospective design of the current study, we were able to 
describe corresponding associations between predictors and survival outcome rather than 
establishing causality. In fact, such an observational retrospective study can only provide 
information on the effectiveness of modalities rather than any causality between modality and 
mortality (Yang et al., 2015).  Ideally prospective and case control study designs would be the 
most suitable for comparing the survival outcomes between different dialysis modalities. Non-
random individual selection and assignment of patients to dialysis modality did not allow us to 
adjust for potential biases. Even though in some cases it is not possible to randomly assign 
patients to different modalities, appropriate statistical methods, particularly those using time-
varying covariates, will allow for more robust comparison of survival outcome in different 
modalities. For instance, time-varying measurements of variables such as HTN would help to 
better understand how well dialysis patients may respond to dialysis therapy. Therefore, cross-
  
88 
sectional analysis of variables in this study, instead of multiple time dependent values is a major 
limitation of this study.  
Another limitation of this study is lack of adjustment for some of the important variables, 
due to either the retrospective study design, data quality issues or insufficient information such 
as laboratory values, nutritional status, smoking, ethnicity and quality of life. Any of these 
factors could potentially confound the association of predictors and survival outcome and 
therefore could result in biased estimates in the study. Since information extracted from 
Nephrocare and Nephroport was mainly collected for clinical records, it may not contain 
variables important to addressing the research questions.  
Despite adjusting for various comorbidities and mental disorders, binary categorization 
(analysis) did not necessarily account for the severity level of those disease at the baseline in this 
analysis. Incomplete information on comorbidities such as duration of medication treatment and 
the stage of the diseases in this cohort could have influenced the results. Hence, it is likely that 
patients with different levels of disease severity and duration were categorized under the same 
group.  
Although hospital-based data of the current research provides enough of eligible patients for 
the analysis, the study findings are prone to confounding by unmeasured variables such as socio-
demographic factors and known confounders in this context, like modality switches. It is worth 
mentioning that studies that accounted for modality switches did not find significant differences 
in their survival outcomes (Perl et al., 2011).  
       Even though relevant insights have been extracted from this study, these findings may not be 
generalizable to other cohorts due to some reasons such as the retrospective observational design 
of the study, and differences in clinical practices and patients’ characteristics across different 
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centers and countries. The data used for this study was extracted from a single center and may 
not reflect the survival outcome in other study sites. Moreover, the results of this study were not 
confirmed by applying propensity score matching to control confounding factors and overcome 
the limitation of non-random allocation of patients to HD and PD (Choi et al., 2013). Finally, 
treating all censoring as independent of survival outcome is a potential limitation of this study 
and might have led to biased results.  
6.3.3. Implications and future directions  
Based on the findings and limitations of this study, some new research questions have 
been raised that could lead to topics for future studies. For instance, detailed analysis of survival 
outcome by initiation year could be performed to further evaluate the survival trend in GRH. 
Future studies accounting for modality switches and time-variant measurements of modalities are 
needed to provided robust evidence on the effectiveness of dialysis options, which could 
eventually lead to better choices among alternatives.  
A prospective, case-control study would allow assessment of important variables such as 
quality of life, smoking status and race as important predictors. Adjusting the Cox model for 
variables such as BMI and critical laboratory variables would better represent the modality 
comparison and increase the credibility of the results.  For better prognostics, a clinical and 
laboratory time-varying covariate approach capturing the dynamic of the indicators over time is 
suggested.  
It is often argued that backward elimination variable selection is more efficient than 
forward since the importance of the variable is not assessed in the context of other variables 
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(Guyon et al., 2003). Although in this study backward elimination was found to be preferable to 
forward, other techniques such as lasso -a robust technique- is strongly suggested.  
Also the use of propensity score matching method in future studies is recommended to 
adequately control for potential confounding factors and so overcome the non-randomized 
allocation of dialysis patients to different modalities (Choi et al., 2013). Further large-scale 
cohort studies in Canada with sophisticated study designs are required to confirm the similar 
outcome of PD and HD modalities.  
 
6.4. Conclusions  
Cox proportional hazard model and KM survival curves were developed to identify the 
association of different variables with survival outcome and to estimate the survival experience 
of dialysis patients over a period of 5 years. This study showed acceptable survival rates for 
chronic dialysis patients in GRH, a significant protective impact of HTN, non-significant impact 
of modality on survival outcome and similar outcome for both HD and PD techniques during the 
study follow-up. Although the initial advantage for PD was greater than that of HD, long-term 
results were equivalent for both modalities in GRH. Following the findings of this study, PD and 
HD can be equally offered to all incident dialysis patients. As a result, more focus should go 
towards the quality of life and goals of therapy at the stage of care planning with patients.  
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Appendices 
     Appendix A- Context data 
ref Aim of the study Publication 
date 
Huang et al. 
 
Comparing survival in patients on PD/HD modalities, estimating 
survival rate and mortality hazard in PD and HD patients in Taiwan 
2008 
Andrikos et 
al. 
Comparing survival rate between PD and HD modalities.  2008 
Lee et al. 
 
Analysing modality-related mortality in long term among PD and HD 
dialysis patients (identifying impact of different modalities on 
morality).  
2009 
Sens et al. 
 
Comparing survival outcome between HD and PD in ESRD patients 
with CHF 
 
2011 
Sood et al.  
 
Explore the effect of type of modality (PD, HD) on all-cause mortality 
among Aboriginal and Caucasian patients and also to investigate 
survival rate among them. 
 Examine potential differences by type of modality among two groups 
of patients’ in Canada: Aboriginal and Caucasian  
2012 
Yeates et al. 
 
Comparing and studying PD survival outcome relative to HD in 
Canada,  
2012 
Choi et al. 
 
Examining the impact of modality on survival, comparing survival in 
two groups of dialysis patients (HD,PD) 
2013 
Madziarska 
et al. 
Identifying factors that have a significant impact on survival, identifying 
differences in the efficiency of PD and HD modalities  
2013 
Wang et al. 
 
Comparing survival rate in PD and HD in incident ESRD patients with 
CAD or CHF 
2013 
Kim et al. Comparing survival between incident HD and PD dialysis patients 
 
2014 
Serafinceanu 
et al.  
Identify predictors (clinical and demographic ones) that significantly 
associate with early mortality in diabetic patients who are incident to 
dialysis 
2014 
Marshall et 
al. 
 
Comparing and examining temporal changes in survival among patients 
undergoing facility HD, home HD and PD. Examining the era effect in 
dialysis population in which change in mortality risk with dialysis 
modality over time accounting for patient, treating center, competing 
risk of transplantation.  
2015 
Yang et al. 
 
comparing the survival outcome of ESRD patients on different 
modalities (HD/PD) 
2015 
Wang et al. 
 
Comparing survival between HD and PD in ESRD patients with prior 
stroke 
2016 
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    Appendix B- Quantitative and qualitative findings 
Study Main findings Significant 
variables 
Survival rate 
Sood et al. 
(2008) 
Type of modality affects Aboriginal 
patients’ survival. This group on PD 
experience higher rate of mortality 
and technique failure compared to 
Caucasian.  
Risk of mortality and technique 
failure is higher among younger 
(under 50) patients undergoing PD 
dialysis.  
Age as a 
significant 
modifier, race X 
modality 
1 year, 2-year, 5-year, 8-year, 
10-year (Aboriginal-
Caucasian) 
HD:  PD:  
0.83 
0.63 
0.4 
0.27 
0.2 
0.83 
0.63 
0.42 
0.3 
0.28 
0.95 
0.84 
0.61 
0.47 
0.35 
0.98 
0.86 
0.68 
0.56 
0.5 
Serafinceanu et 
al. (2014) 
Hemodialysis used as a first/single 
method for RRT and the LI of 
dialysis were identified as the 
significant factors that affect 
survival 
the use of HD 
and the Late 
initiation of 
dialysis 
1 year, 2-year, 3-year, 4-year, 
5-year  
PD: 
0.3 
0.22 
0.1 
HD: 
0.22 
0.17 
0.07 
Yang et al. 
(2015) 
Risk of mortality is reported higher 
among incident dialysis patients 
initiate PD dialysis compared to that 
of incident dialysis patients 
undergoing HD  
PD modality, age 
group, diabetes, 
cardiovascular 
disease 
5-year survival (whole 
cohort, propensity score 
matched subsample): 
PD: HD: 
0.2 
 
0.2 0.62 
 
 
0.5 
Huang et al. 
(2008) 
Age, comorbidities condition, 
diabetes and gender are the most 
significant modifiers of the impact 
of modality on survival outcome. 
Survival outcome is the same for 
PD and HD patients in long term. 
Older patients with diabetes have a 
better survival on HD.  
Age, sex, 
comorbid 
conditions, 
primary renal 
disease (DM, vs 
non-DM) 
1 year, 2-year, 3-year, 5-year, 
7-year, 10-year 
PD: 
0.898  
0.776  
0.676 
0.555 
0.479 
0.35 
HD: 
0.875 
0.766 
0.681 
0.543 
0.442 
0.338 
Marshall et al. 
(2015) 
Better survival among PD patients 
compared to home HD.  
 
 
n/a 1 year, 2-year, 3-year, 4-year, 
5-year 
PD: 
0.95 
0.85 
0.7 
0.6 
0.45 
HD: 
0.9 
0.8 
0.7 
0.6 
0.5 
Choi et al. 
(2013) 
-Patients under 65 years without 
diabetes have a better survival under 
PD than HD. Patients after 90 days 
of dialysis initiation whether PD or 
Older age, lower 
BMI, and 
fewer 
comorbidities, 
6-month, 1-year, 18-month, 
2-year survival 
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HD showed similar survival 
outcome. 37% lower risk of 
mortality among PD patients 
compared to HD (Cox model). 51% 
lower risk of mortality patients 
under PD compared to HD.  
including 
congestive heart 
failure and peptic 
ulcer disease 
PD: 
0.993 
0.969 
0.958 
0.943 
HD: 
0.989 
0.941 
0.906 
0.876 
 
Yeates et al. 
(2012) 
Similar survival outcome for both 
HD and PD modalities.  
 
 
n/a 
 
1-year survival, 2 year 
survival, 4-year, 5years 
PD: 
0.9 
0.72 
0.6 
0.45 
0.38 
HD: 
0.85 
0.72 
0.66 
0.55 
0.4 
Kim et al. 
(2014) 
Higher rate of mortality among PD 
dialysis patients than in HD 
modality (before and after applying 
propensity score matched group). 
Among older patients (>55 years) 
the mortality rate consistently 
higher in PD. While in the younger 
group no significant difference in 
the mortality rate has been shown 
Age at the 
initiation of 
dialysis, 
1-year, 2-year, 3-year, 4-year 
PD: 
0.90 
0.79 
0.71 
0.6 
 
 
HD: 
0.87 
0.78 
0.72 
0.63 
Madziarska et 
al. (2013) 
Type of modality does not impact 
on survival outcome.  
Elevated cholesterol level associates 
with better survival in HD patients. 
Advanced age associates with worse 
survival in PD patients.  
Serum Albumin 
(whole 
population) 
Cholesterol level 
(HD) 
Age (PD) 
1 year, 2-year, 3-year, 4-year 
PD: 
0.7 
0.5 
0.44 
0.33 
 
HD: 
0.87 
0.58 
0.42 
0.33 
 
 
Lee et al. 
(2009) 
Rate of mortality was not 
significantly different in PD and HD 
group. Dialysis modality has no 
significant impact on all-cause or 
infectious related mortality  
 
n/a 1 year, 2-year, 3-year, 4-year, 
5-year 
PD: 
0.9 
0.8 
0.78 
0.7 
0.63 
HD: 
0.95 
0.85 
0.8 
0.75 
0.68 
Wang et al. 
(2013) 
PD modality is associated with 
poorer survival among ESRD 
patients with CVD or diabetes 
compared to PD.  
Both non-diabetic and diabetic 
patients undergoing PD dialysis 
modality with or without CAD or 
CHF, have poorer survival outcome.  
 
Gender, 
Comorbidities 
such as CAD, 
CHF, neoplasm 
, chronic 
hepatitis, 
cerebrovascular 
disease and 
chronic 
obstructive 
pulmonary 
disease 
1 year, 2-year, 3-year, 4-year, 
5-year, 6-year. 7-year, 8-year, 
9-year, 10 year 
PD: 
0.95 
0.91 
0.86 
0.82 
0.79 
0.74 
0.70 
0.66 
 
 
HD: 
0.93 
0.88 
0.83 
0.80 
0.77 
0.73 
0.69 
0.66 
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0.62 
0.58 
0.63 
0.61 
 
Sens et al. 
(2011) 
PD was associated with higher rate 
of mortality in all sub groups. 
Rate of cardiovascular death was 
higher in PD dialysis patients.  
age, NYHA stage 
III–IV CHF, 
CVC use at first 
dialysis 
session, PVD, 
liver cirrhosis, 
and behavior 
disturbance 
1 year, 2-year, 3-year, 4-year, 
5-year 
PD: 
0.68 
0.43 
0.3 
0.23 
0.16 
 
HD: 
0.73 
0.6 
0.5 
0.4 
0.3 
Wang et al. 
(2016) 
Overall survival is poorer for 
patients with diabetes and prior 
stroke undergoing PD. Similar 
outcome for both HD and PD 
modality among non-diabetic 
patients with stroke. Gender is the 
main contributor to the mortality 
differences among PD and HD 
patients.  
 
 
Gender, diabetes 1 year, 2-year, 3-year, 4-year, 
5-year 
 
PD: 
0.83 
0.67 
0.54 
0.44 
0.35 
HD: 
0.81 
0.63 
0.59 
0.47 
0.41 
 
Andrikos et al. 
(2008) 
Using AT approach, patients 
undergoing PD have better survival. 
Using ITT approach, similar 
outcome for both modalities.  
 
n/a 1 year, 2-year, 3-year, 4-year, 
5-year, (AT, ITT) 
 
PD: HD: 
0.94 
0.82 
0.79 
0.79 
 
0.89 
0.77 
0.57 
0.55 
0.92 
0.8 
0.55 
0.57 
0.94 
0.57 
0.53 
0.51 
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Appendix C- Cohort summary 
ref Cohort size/incident on modalities Dataset Follow-
up 
duration 
Modality 
condition 
Study design 
Sood et al. 
(2012) 
31576 Canadian 
Organ 
Replacement 
Registry 
(CORR) 
January 
1, 2000 to 
December 
of 2009 
Assigned 
modality 
after 90 
days 
dialysis 
initiation 
Intention to 
treat analysis 
retrospective 
HD 
Aboriginal=1839 
Caucasian=21430 
PD 
Aboriginal=554 
Caucasian=6769 
Serafinceanu 
et al. (2014) 
788 Dialysis 
Center of 
NIDNMD 
Paulescu, 
Bucharest 
January 
1996 to 
December 
2005 
 Retrospective 
case-control 
study 
Yang et al. 
(2015) 
871 National 
University 
Hospital 
(NUH), 
Singapore 
2005-
2010 
survived 
the first 90 
days of 
dialysis 
Observational 
prospective HD= 641 PD=230 
Huang et al. 
(2008) 
48629 Taiwan Renal 
Registry 
1995-
2002 
survived 
for the first 
90 days 
on dialysis 
Retrospective 
(intention-to-
treat 
paradigm) 
HD=45820 PD=2809 
Marshall et 
al. (2015) 
37552 The Australia 
and New 
Zealand 
Dialysis and 
Transplant 
Registry 
(ANZDATA). 
March 31, 
1998 - 
December 
31, 2012. 
n/a observational 
inception 
cohort study- 
as treated 
paradigm 
prospective  
Facility HD: 
20890 
PD: 
13220 
Home HD: 
3442 
Choi et al. 
(2013) 
1060 Data was 
collected 
from 31 
hospitals 
affiliated with 
CRC 
September 
1, 2008 
and June 
30, 2011 
Modality 
defined as 
90 days 
after the 
first 
dialysis 
nationwide 
prospective 
observational 
(intention-to-
treat analysis) 
HD: 736 PD= 324 
Yeates et al. 
(2012) 
46839 
 
Canadian 
Organ 
Replacement 
Register 
(CORR) 
1991-
2004 
With 
follow-up 
to 2007 
Initial 
modality 
considered 
as modality 
90 days 
after 
the first 
service date  
Intention to 
treat analysis 
(PH-model) 
As-treated 
(non PH-
model) 
HD: 
32531 
PD: 
14308 
Kim et al. 
(2014) 
32280 Korean 
Health 
Insurance 
Review & 
Assessment 
Service 
database 
26.5 
month 
(2005-
2008) 
Survived 
more than 
90 after 
dialysis 
initiation  
Intention to 
treat analysis 
HD:24399 PD: 7881 
  
105 
Madziarska 
et al. (2013) 
61 three dialysis 
centers in 
south-west 
Poland 
2006-
2010 
Being on 
maintance 
dialysis for 
at least 60 
days 
Prospective 
PD:26 HD:35 
Lee et al. 
(2009) 
1347 Chang 
Gung 
Memorial 
Hospital, 
Keelung, 
Taiwan 
May 1991 
and 
October 
2005 
Being on 
dialysis for 
more than 
90 days 
Prospective 
study in a 
single center 
PD: 258 HD: 1089 
Wang et al. 
(2013) 
35664 National 
Health 
Insurance 
Research 
Database 
(NHIRD) 
1997 to 
2007 
Dialysis 
modality at 
day 90  
Retrospective 
matched 
cohort study PD: 
5944 
HD: 
29720 
Sens et al. 
(2011) 
4401 French Renal 
Epidemiology 
and 
Information 
Network 
(REIN) 
Registry 
2002 to 
2008 
modality at 
day 90 
after first 
dialysis or 
the one at 
dialysis 
initiation if 
death 
occurred 
before the 
90th day. 
 
Prospective 
PD:933 HD:3468 
Wang et al. 
(2016) 
2857 National 
Health 
Insurance 
Research 
Database 
(NHIRD) 
2000 to 
2010 
Undergoing 
dialysis for 
at least 90 
days  
Retrospective 
PD: 
982 
HD: 
1875 
Andrikos et 
al. (2008) 
94 Nephrology 
department, 
G. Hatzikosta 
general 
hospital, 
Ioannina, 
Greece 
January 
1995 to 
December 
2000 
Being 
survived at 
least 90 
days 
Retrospective 
(AT and ITT 
analysis) PD: 
48 
HD: 
46 
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Appendix D- executive summary of evidence for survival outcome 
 
 
1-year 
 
2-year 3-year 4-year 5-year 
PD HD PD HD PD HD PD HD PD HD 
Sood et al. (2008) 0.95 0.83 0.84 0.63 0.61 0.4 0.47 0.27 0.35 0.2 
Serafinceanu et al. (2014) 0.1 0.07  - -  -  -  -  -  -  -  
Yang et al. (2015) 0.8 0.9 0.65 0.8 0.4 0.73 0.28 0.7 0.2 0.62 
Huang et al. (2008) 0.89 0.87 0.77 0.76 0.67 0.68 0.6 0.6 0.55 0.54 
Marshall et al. (2015) 0.95 0.9 0.85 0.8 0.7 0.7 0.6 0.6 0.45 0.5 
Choi et al. (2013) 0.96 0.94 0.94 0.87  - -  -  -  -  -  
Yeates et al. (2012) 0.9 0.85 0.72 0.72 0.6 0.66 0.45 0.55 0.38 0.4 
Kim et al. (2014) 0.9 0.87 0.79 0.78 0.71 0.72 0.6 0.63  -  - 
Madziarska et al. (2013) 0.7 0.87 0.5 0.58 0.44 0.42 0.33 0.33  - -  
Lee et al. (2009) 0.9 0.95 0.8 0.85 0.78 0.8 0.7 0.75 0.63 0.68 
Wang et al. (2013) 0.95 0.93 0.91 0.88 0.86 0.83 0.82 0.8 0.79 0.77 
Sens et al. (2011) 0.68 0.73 0.43 0.6 0.3 0.5 0.23 0.4 0.16 0.3 
Wang et al. (2016) 0.83 0.81 0.67 0.63 0.54 0.59 0.44 0.47 0.35 0.41 
Andrikos et al. (2008) 0.94 0.92 0.82 0.8  -  - 0.79 0.57 0.79 0.55 
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Appendix F- Log-rank test (age categories) 
  Number of patients Observed Expected (O-E)^2/E  (O-E)^2/V 
Age   
       18-44 80 8 42.4 27.95 32.83 
       45-54 78 11 32.7 14.43 16.18 
       55-64 156 56 68.6 2.31 2.99 
       65-74 227 98 86.2 1.63 2.27 
        >75 217 134 77.1 42.05 56.45 
  Chisq= 89.1  on 4 degrees of freedom, p= 0  
 
Appendix G- Log-rank test (gender) 
 
 
 
Log-Rank test 
 Number 
of patients Observed Expected (O-E)^2/E  (O-E)^2/V 
Gender   
male 453 184 175 0.48 1.25 
female 270 100 109 0.769 1.25 
   Chisq= 1.3  on 1 degrees of freedom, p= 0.263 
 
Appendix H- Log-rank test (modality) 
  Number of patients Observed Expected (O-E)^2/E  (O-E)^2/V 
Modality   
    HD 592 238 233.3 0.0949 0.536 
    PD 131 46 50.7 0.4366 0.536 
   Chisq= 0.5  on 1 degrees of freedom, p= 0.464 
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Appendix I- Backward elimination procedure  
 
 
 
Step  Variables Adjusted HR 95% CI P-value 
1         
 
Age 1.05 1.04    1.06 <0.001 
 
Gender 0.86 0.67    1.11 0.239 
 
Modality 0.88 0.64    1.22 0.450 
 
Dementia 0.79 0.50    1.27 0.331 
 
Bipolar 1.95 0.83    4.61 0.127 
 
Depression 1.04 0.79    1.36 0.789 
 
HTN 0.62  0.41    0.93 0.020 
 
Cardiac disease 0.91 0.68    1.22 0.542 
 
CVA 0.94 0.72    1.23 0.673 
 
MI 0.88 0.66    1.19 0.416 
 
Lung disease 1.21  0.92    1.59 0.170 
 
Diabetes 1.12 0.86    1.47 0.386 
 
Cancer 0.95 0.74    1.22 0.664 
2         
 
Age 1.05  1.04    1.06 <0.001 
 
Gender 0.86 0.67    1.10 0.239 
 
Modality 0.88 0.64    1.22 0.454 
 
Dementia 0.80 0.50    1.27 0.344 
 
Bipolar 1.99 0.85    4.65 0.112 
 
HTN 0.62 0.41    0.93 0.021 
 
Cardiac disease 0.92 0.68    1.22 0.551 
 
CVA 0.94 0.72    1.24 0.675 
 
MI 0.88  0.66    1.19 0.417 
 
Lung disease 1.22  0.93    1.59 0.153 
 
Diabetes 1.13  0.86    1.47 0.379 
 
Cancer 0.94  0.73    1.21 0.654 
3         
 
Age 1.05  1.04    1.06 <0.001 
 
Gender 0.86  0.67    1.11 0.251 
 
Modality 0.88  0.64    1.22 0.439 
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Dementia 0.79  0.50    1.25 0.306 
 
Bipolar 1.97 0.84    4.60 0.117 
 
HTN 0.61 0.41    0.92 0.018 
 
Cardiac disease 0.91 0.68    1.22 0.535 
 
MI 0.88 0.66    1.19 0.404 
 
Lung disease 1.21 0.93    1.58 0.162 
 
Diabetes 1.12 0.86    1.47 0.389 
 
Cancer 0.95 0.74    1.22 0.669 
4         
 
Age 1.05 1.04    1.06 <0.001 
 
Gender 0.87 0.68    1.11 0.256 
 
Modality 0.89 0.64    1.22 0.455 
 
Dementia 0.79 0.50    1.25 0.305 
 
Bipolar 1.97 0.85    4.61 0.116 
 
HTN 0.62 0.41    0.92 0.019 
 
Cardiac disease 0.91 0.68    1.21 0.519 
 
MI 0.88 0.65    1.18 0.387 
 
Lung disease 1.21 0.93    1.59 0.155 
 
Diabetes 1.13 0.87    1.47 0.377 
5         
 
Age 1.05  1.04    1.06 <0.001 
 
Gender 0.86 0.67    1.10 0.240 
 
Modality 0.88 0.64    1.21 0.433 
 
Dementia 0.78 0.50    1.24 0.303 
 
Bipolar 1.94 0.83    4.53 0.124 
 
HTN 0.60 0.40    0.90 0.012 
 
MI 0.84 0.65    1.09  0.183 
 
Lung disease 1.20 0.92    1.57  0.172 
 
Diabetes 1.12 0.86    1.46 0.404 
6         
 
Age 1.05 1.04    1.06 <0.001 
 
Gender 0.86 0.67    1.10 0.240 
 
Dementia 0.80 0.51    1.26 0.336 
 
Bipolar 1.95 0.83    4.54 0.123 
 
HTN 0.60 0.40    0.89 0.012 
 
MI 0.84 0.65    1.09 0.191 
 
Lung disease 1.21 0.93    1.57 0.164 
 
Diabetes 1.11 0.85    1.44 0.451 
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7         
 
Age 1.05 1.04     1.06 <0.001 
 
Gender 0.86 0.67     1.11 0.241 
 
Dementia 0.80 0.51     1.27 0.343 
 
Bipolar 1.99 0.86     4.64 0.109 
 
HTN 0.62 0.42     0.92 0.016 
 
MI 0.85  0.65     1.10 0.207 
 
Lung disease 1.21  0.93     1.58 0.150 
8         
 
Age 1.05 1.04    1.06 <0.001 
 
Gender 0.87 0.68    1.11 0.258 
 
Bipolar 1.80 0.79    4.09 0.159 
 
HTN 0.61 0.42    0.90 0.012 
 
MI 0.85 0.66    1.11 0.232 
 
Lung disease 1.23 0.94    1.60 0.128 
9         
 
Age 1.05 1.04    1.06    <0.001 
 
Bipolar 1.76 0.78    3.98 0.177 
 
HTN 0.63 0.43    0.92 0.017 
 
MI 0.87 0.67    1.12 0.278 
10 
Lung disease 
  
1.22 
  
0.94    1.59 
  
0.140 
  
  Age 1.05 1.04    1.06 <0.001 
  Bipolar 1.74 0.77    3.94 0.184 
  HTN 0.62 0.43    0.91 0.013 
  
11 
Lung disease 
  
1.21 
  
0.93    1.58 
  
0.154 
  
 
Age 1.05 1.04    1.06 <0.001 
 
HTN 0.63  0.43    0.91 0.015 
 
Lung disease 1.20  0.92    1.56 0.173 
12         
 
Age 1.05 1.04    1.06 <0.001 
 
HTN 0.65 0.45    0.94 0.023 
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 Glossary  
 
ACR Albumin to Creatinine Ratio 
“The first method of preference to detect elevated protein; ACR is calculated by dividing albumin 
concentration in milligrams by creatinine concentration in grams.”1 
BMI Body Mass Index 
“An indicator of body density as determined by the relationship of body weight to body height. 
BMI=weight (kg)/height squared (m2).”2 
CAD Coronary Artery Disease 
“Pathological processes of coronary arteries that may derive from a congenital abnormality, 
atherosclerotic, or non-atherosclerotic cause.”3 
CAPD Continuous Ambulatory Peritoneal Dialysis 
“Portable peritoneal dialysis using the continuous (24 hours a day, 7 days a week) presence of 
peritoneal dialysis solution in the peritoneal cavity except for periods of drainage and instillation of 
fresh solution.”4 
CCPD Continuous Cycling Peritoneal Dialysis 
“A type of dialysis in which the patient is attached to an automatic cycler for short exchanges while 
sleeping at night. Mobility is not feasible because of the cumbersome equipment. During waking hours 
the patient receives long dialysis exchanges but has ambulatory freedom.”5 
CHF Congestive Heart Failure 
“Heart failure in which the heart is unable to maintain adequate circulation of blood in the 
tissues of the body or to pump out the venous blood returned to it by the venous 
circulation”6 
CI Confidence Interval 
“A confidence interval gives an estimated range of values which is likely to include an unknown 
population parameter, the estimated range being calculated from a given set of sample data.”7 
CKD Chronic Kidney Disease 
“Conditions in which the kidneys perform below the normal level for more than three months. Chronic 
kidney insufficiency is classified by five stages according to the decline in Glomerular Filtration 
Rate and the degree of kidney damage.”8 
CORR Canadian Organ Replacement Register 
                                                
1National Kidney Foundation, (2017). Retrieved from: 
 https://www.kidney.org/kidneydisease/siemens_hcp_acr 
2 Body Mass Index. (n.d.). In Medical Dictionary Online. Retrieved from: 
 https://www.online-medical-dictionary.org/definitions-b/body-mass-index.html 
3 Coronary Artery Disease. (n.d.). In Medical Dictionary Online. Retrieved from: 
 https://www.online-medical-dictionary.org/definitions-c/coronary-artery-disease.html 
4 Continuous Ambulatory Peritoneal Dialysis. (n.d.). In Medical Dictionary Online. Retrieved from: 
https://www.online-medical-dictionary.org/definitions-p/peritoneal-dialysis-continuous-ambulatory.html 
5 Continuous Cycling Peritoneal Dialysis. (2009). In Medical dictionary online. Retrieved from: 
https://medical-dictionary.thefreedictionary.com/continuous+cycling+peritoneal+dialysis 
6 Congestive Heart Failure. (n.d.). In Medical Dictionary Online. Retrieved from: 
 https://www.merriam-webster.com/dictionary/congestive%20heart%20failure#medicalDictionary 
7 Confidence Interval. (n.d.). In Valerie J. Easton and John H. McColl's Statistics Glossary v1.1. Retrieved from: 
http://www.stat.yale.edu/Courses/1997-98/101/confint.htm 
8 Chronic Kidney Disease. (n.d.). In Medical Dictionary Online. Retrieved from: 
 https://www.online-medical-dictionary.org/definitions-r/renal-insufficiency-chronic.html 
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CVA Cerebrovascular Accident  
“The sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is 
impaired by blockage or rupture of an artery to the brain. A CVA is also referred to as a stroke.”1 
DBP Diastolic Blood Pressure 
“The lowest arterial blood pressure of a cardiac cycle occurring during diastole of the 
heart.”2 
DOPPS Dialysis Outcomes and Practice Patterns Study 
ESRD End-Stage Renal Disease 
“The end-stage of chronic renal insufficiency. It is characterized by the severe irreversible kidney 
damage and the reduction in Glomerular Filtration Rate to less than 15 ml per min.”3 
GFR Glomerular Filtration Rate 
“The volume of water filtered out of plasma through glomerular capillary walls into 
Bowman's capsules per unit of time. It is considered to be equivalent to insulin clearance.”4 
GRH Grand River Hospital 
GOF Goodness of Fit 
“The conformity between an experimental result and theatrical expectation or between data and an 
approximating curve”5 
HD Hemodialysis 
“Separation of soluble substances and water from the blood by diffusion through a semipermeable 
membrane; separation of cellular elements and colloids from soluble substances is achieved by pore 
size in the membrane and rates of diffusion.”6 
HF Hemofiltration 
"The process of removing blood from the living body (as of a kidney patient), purifying it 
by passing it through a system of extracorporeal filters, and returning it to the body.”7 
HR Hazard Ratio 
“A theoretical measure of the probability of occurrence of an event per unit time at risk”.8 
HTN Hypertension 
“Hypertension is high blood pressure. Blood pressure is the force of blood pushing against the walls of 
arteries as it flows through them. Arteries are the blood vessels that carry oxygenated blood from the 
heart to the body's tissues.”9 
                                                
1 Cerebrovascular Accident. (n.d.). In MedTerm dictionary. Retrieved from: 
https://www.medicinenet.com/script/main/art.asp?articlekey=2676 
2 Diastolic Blood Pressure. (n.d.). In Merriam Webster Medical Dictionary. Retrieved from: 
 https://www.merriam-webster.com/medical/diastolic%20blood%20pressure 
3 ESRD. (n.d.). In Medical Dictionary Online. Retrieved from: 
https://www.online-medical-dictionary.org/definitions-k/kidney-failure-chronic.html 
4 Glomerular Filtration Rate. (n.d.). In Medical Dictionary Online. Retrieved from: 
 https://www.online-medical-dictionary.org/definitions-g/glomerular-filtration-rate.html 
5 Goodness of Fit. (n.d.). In Merriam Webster Dictionary. Retrieved from: 
 https://www.merriam-webster.com/dictionary/goodness%20of%20fit 
6 Hemodialysis. (n.d.). In The free dictionary by Farlex. Retrieved from: 
 https://medical-dictionary.thefreedictionary.com/haemodialysis 
7 Hemofiltration. (n.d.). In Merriam Webster Medical Dictionary. Retrieved from: 
 https://www.merriam-webster.com/medical/hemofiltration 
8 Hazard Ratio. (2014). In A dictionary in Epidemiology). Retrieved from: 
http://www.oxfordreference.com/view/10.1093/acref/9780199976720.001.0001/acref-9780199976720-e-2181 
9 Hypertension. (n.d.). In The free dictionary by Farlex. Retrieved from:  
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IHD Ischemic Heart Disease 
“A pathological condition caused by lack of oxygen in cells of the myocardium.”1 
NKF National Kidney Foundation 
OR Odds Ratio 
“A measure of association used in comparative studies, particularly case-control studies, that quantifies 
the association between an exposure and a health outcome; also called the cross-product ratio.”2 
ORN Ontario Renal Network 
PD Peritoneal Dialysis 
“Dialysis fluid being introduced into and removed from the peritoneal cavity as either a continuous or 
an intermittent procedure.”3 
PVD Peripheral Vascular Disease 
“Pathological processes involving any one of the blood vessels in the vasculature outside the heart.”4 
RRT Renal Replacement Therapy 
“Procedures which temporarily or permanently remedy insufficient cleansing of body fluids by the 
kidneys.”5 
SBP Systolic Blood Pressure 
“the highest arterial blood pressure of a cardiac cycle occurring immediately after systole 
of the left ventricle of the heart”.6 
USRDS United States Renal Data System 
 
                                                                                                                                                       
https://medical-dictionary.thefreedictionary.com/hypertension 
1 Ischemic Heart Disease. (2009). In Mosby's Medical Dictionary, 9th edition, Elsevier. Retrieved from: 
https://medical-dictionary.thefreedictionary.com/ischemic+heart+disease 
2 Odds Ratio. (2014). In Principles of Epidemiology in Public Health Practice, Third Edition, An Introduction to 
Applied Epidemiology and Biostatistics. Retrieved from: 
https://www.cdc.gov/ophss/csels/dsepd/ss1978/glossary.html 
3 Peritoneal dialysis. (n.d.). In Medical Dictionary Online. Retrieved from:  
https://www.online-medical-dictionary.org/definitions-p/peritoneal-dialysis.html 
4 Peripheral Vascular Disease. (n.d.). In Medical Dictionary Online. Retrieved from: 
 https://www.online-medical-dictionary.org/definitions-p/peripheral-vascular-diseases.html 
5 Renal Replacement Therapy. (n.d.). In Medical Dictionary Online. Retrieved from: 
 https://www.online-medical-dictionary.org/definitions-r/renal-replacement-therapy.html 
6 Systolic Blood Pressure. (n.d.). In Merriam Webster Medical Dictionary. Retrieved from: 
 https://www.merriam-webster.com/medical/systolic%20blood%20pressure 
 
